###begin article-title 0
Loci controlling lymphocyte production of interferon gamma after alloantigen stimulation in vitro and their co-localization with genes controlling lymphocyte infiltration of tumors and tumor susceptibility
###end article-title 0
###begin p 1
###xml 214 225 214 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf1&#8211;Lynf4</italic>
###xml 638 640 630 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 640 642 632 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pz</italic>
###xml 640 642 632 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>pz</italic></sup>
###xml 705 707 697 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 707 708 699 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 707 708 699 700 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></sup>
###xml 724 726 716 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 726 727 718 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 726 727 718 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>d</italic></sup>
###xml 803 804 791 792 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 938 949 922 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr4-Cypr7</italic>
###xml 1005 1009 989 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf</italic>
###xml 105 113 <span type="species:ncbi:9606">patients</span>
###xml 266 271 <span type="species:ncbi:10090">mouse</span>
###xml 580 584 <span type="species:ncbi:10090">mice</span>
###xml 627 631 <span type="species:ncbi:10090">mice</span>
###xml 729 733 <span type="species:ncbi:10090">mice</span>
###xml 805 809 <span type="species:ncbi:10090">mice</span>
Low infiltration of lymphocytes into cancers is associated with poor prognosis, but the reasons why some patients exhibit a low and others a high infiltration of tumors are unknown. Previously we mapped four loci (Lynf1-Lynf4) controlling lymphocyte infiltration of mouse lung tumors. These loci do not encode any of the molecules that are involved in traffic of lymphocytes. Here we report a genetic relationship between these loci and the control of production of IFNgamma in allogeneic mixed lymphocyte cultures (MLC). We found that IFNgamma production by lymphocytes of O20/A mice is lower than by lymphocytes of OcB-9/Dem mice (both H2pz) stimulated in MLC by irradiated splenocytes of C57BL/10SnPh (H2b) or BALB/cHeA (H2d) mice, or by ConA. IFNgamma production in MLCs of individual (O20 x OcB-9)F2 mice stimulated by irradiated C57BL/10 splenocytes and genotyped for microsatellite markers revealed four IFNgamma-controlling loci (Cypr4-Cypr7), each of which is closely linked with one of the four Lynf loci and with a cluster of susceptibility genes for different tumors. This suggests that inherited differences in certain lymphocyte responses may modify their propensity to infiltrate tumors and their capacity to affect tumor growth.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 357 358 357 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 488 489 488 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 586 587 586 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 589 590 589 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 695 696 695 696 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 744 745 744 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 841 842 841 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 882 883 882 883 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1381 1382 1381 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 627 632 <span type="species:ncbi:9606">human</span>
###xml 1012 1020 <span type="species:ncbi:9606">patients</span>
Interaction between the immune system and cancer is one of the most important determinants of cancer growth, progression, and metastasis. The interconnected processes of innate and adaptive immunity co-determine the development of cancer from the very beginning, when acute inflammation tends to suppress and chronic inflammation to promote carcinogenesis [1]. The interaction of adaptive immunity with cancer is less clear. It is a powerful agent in rejection of virally induced tumors [2], but its effects on spontaneous and carcinogen-induced tumors are still subject of discussion [3, 4]. Recently, however, in a number of human cancers it has been observed that presence of infiltrating CD3+ T lymphocytes is a positive prognostic factor [5], although in some studies their effect was mitigated by presence of T regulatory lymphocytes [6]. This indicated a positive role of CD3+ T lymphocytes in suppression of cancer. However, it is not known why infiltrating T lymphocytes are abundant in cancers of some patients but scarce in others. Although in the past decade, a large progress has been made in unravelling the sequence of molecular steps that participate in the passage of lymphocytes from blood circulation into tumor, and more than 60 different molecules (or closely related members of the same family) that facilitate and mediate lymphocyte traffic were identified [7], differences in structure or expression of these molecules were not yet correlated with individual propensity to tumor infiltration.
###end p 4
###begin p 5
###xml 255 256 255 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 333 338 333 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf1</italic>
###xml 339 344 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf4</italic>
###xml 346 350 346 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf</italic>
###xml 449 450 449 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 531 535 531 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf</italic>
###xml 542 547 542 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf1</italic>
###xml 562 567 562 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf2</italic>
###xml 582 587 582 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf3</italic>
###xml 592 597 592 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf4</italic>
###xml 175 180 <span type="species:ncbi:10090">mouse</span>
To the contrary, a new insight into the regulation of lymphocyte infiltration in tumors has been provided by the observations that the presence of infiltrating lymphocytes in mouse lung tumors is pronounced in some strains but virtually absent in others [8] and that this difference is controlled by four chromosomal loci designated Lynf1-Lynf4 (Lynf = Lymphocyte infiltration) that determine the presence of intra-tumoral infiltrating lymphocytes [9] in a cross between strains O20/A and OcB-9/Dem. Surprisingly, none of the four Lynf loci (Lynf1-chromosome 4; Lynf2-chromosome 8; Lynf3 and Lynf4-chromosome 6) encoded any of set of >60 molecules that were reported to participate in migration of lymphocytes into tumors. Therefore, other processes than direct molecular interactions of lymphocyte and surrounding tissue may be the primary determinants of individual's propensity to lymphocyte infiltration of tumors.
###end p 5
###begin p 6
###xml 206 212 206 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Marif1</italic>
###xml 269 275 265 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Marif2</italic>
###xml 378 380 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 397 403 389 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cinda3</italic>
###xml 408 414 400 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cinda5</italic>
###xml 503 505 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 508 514 500 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Marif1</italic>
###xml 519 525 511 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cinda3</italic>
###xml 555 561 547 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cinda3</italic>
###xml 583 588 575 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf1</italic>
###xml 642 654 634 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sluc6/Sluc21</italic>
###xml 672 678 664 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Marif2</italic>
###xml 683 689 675 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cinda5</italic>
###xml 722 727 714 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf2</italic>
###xml 785 791 777 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sluc20</italic>
###xml 604 609 <span type="species:ncbi:10090">mouse</span>
###xml 746 751 <span type="species:ncbi:10090">mouse</span>
Our previous data showed that genetic polymorphisms of the intensity of nonspecific inflammation-related activity of immunocytes are linked with cancer susceptibility genes. We defined previously two loci, Marif1 controlling production of IL-12, TNFalpha and iNOS, and Marif2 controlling production of TNFalpha and IL-12, by in vitro stimulated bone marrow-derived macrophages [10], and two loci, Cinda3 and Cinda5, controlling in vitro proliferative response of lymphocytes to cytokines IL-2 and IL-4 [11]. Marif1 and Cinda3 are linked to each other and Cinda3 is closely linked to Lynf1 as well as the mouse lung cancer susceptibility loci Sluc6/Sluc21 on chromosome 4. Marif2 and Cinda5 are linked to each other and to Lynf2 as well as to the mouse lung cancer susceptibility locus Sluc20 on chromosome 8. This suggests a possible functional connection between activation of immunocytes and capacity of tumor infiltration.
###end p 6
###begin p 7
###xml 248 250 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 386 389 382 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mls</italic>
###xml 419 422 415 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mtv</italic>
###xml 446 448 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 527 529 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 773 775 769 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 776 778 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 413 418 <span type="species:ncbi:10090">mouse</span>
###xml 511 516 <span type="species:ncbi:9606">human</span>
In the present study, we analysed the genetic control of production of another cytokine, IFNgamma, during in vitro reaction to major histocompatibility complex (MHC) alloantigens. The differences in the MHC antigens induce the strongest responses [12]. But genetic disparity in minor alloantigens also modifies the alloresponse. Earlier studies found that some strong MLC-stimulations (Mls) antigens are coded by mouse Mtv (mammary tumor virus) [13]; later studies revealed a broad spectrum of additional minor human antigens [14]. Intensity of MLC-response to alloantigens is determined by two major factors-the genetic disparity between the responding and stimulating cells and the genetically defined intrinsic capacity of the responding cells to react to the stimulus [15-17].
###end p 7
###begin p 8
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1108 1110 1108 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 1112 1114 1112 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 1178 1183 1178 1183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Alan1</italic>
###xml 1188 1193 1188 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Alan2</italic>
###xml 1371 1373 1371 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 1375 1377 1375 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 1574 1576 1574 1576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
Responder cells react to stimulator cells by proliferation and by cytokine production. We have studied the genetic basis of these two responses, using the recombinant congenic (RC) strains, which were developed for analysis of multigenically controlled biological processes [18]. A series of RC strains is derived from two parental inbred strains: a "background" strain and a "donor" strain. Each of these RC strains contains a different subset of about 12.5% of genes from the parental donor strain and the remaining approximately 87.5% of background strain genes. The BALB/cHeA-c-STS/A (CcS) and O20/A-c-B10.O20/Dem (OcB) series of strains were used previously for analysis of alloantigen response. The strain distribution pattern of magnitude of proliferative response in MLR of individual RC strains to stimulator cells of four different strains was almost identical, indicating that differences in responsiveness, rather than the alloantigenic difference itself, determine the magnitude of the response, and that the responsiveness to different MHC alloantigens is largely controlled by the same genes [19, 20]. We have mapped previously two of these responsiveness genes, Alan1 and Alan2 (Alloantigen response 1, 2) located on chromosomes 17 and 4, respectively, that control differences in proliferative response to several alloantigens in CcS and OcB RC strains [16, 17]. We have also shown that in the individual RCS the levels of proliferation and IL-2 production in MLR are not correlated, and therefore these two responses are under a different genetic control [19].
###end p 8
###begin p 9
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr4</italic>
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr7</italic>
###xml 55 59 55 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr</italic>
###xml 62 81 62 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytokine production</italic>
###xml 304 306 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 399 401 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 402 404 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
In the present work we defined four loci, Cypr4-Cypr7 (Cypr = Cytokine production), that control IFNgamma production by responder cells in MLR. IFNgamma plays important role in immunity against infection, and it has been associated with a number of autoinflammatory and autoimmune diseases (reviewed in [21]). IFNgamma has also multiple and diverse essential functions in immune response to cancer [22-25]. For that reason, genetics of capacity of IFNgamma production may be important for a variety of biological reactions. Here we show that control of IFNgamma production is genetically linked to and possibly responsible for the control of intensity of lymphocyte infiltration in tumors and control of tumor growth and progression.
###end p 9
###begin title 10
Materials and methods
###end title 10
###begin title 11
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 11
###begin p 12
###xml 113 115 113 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 115 117 115 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pz</italic>
###xml 115 117 115 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>pz</italic></sup>
###xml 124 125 124 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 209 211 209 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 211 213 211 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pz</italic>
###xml 211 213 211 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>pz</italic></sup>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 494 496 494 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 496 497 496 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 496 497 496 497 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></sup>
###xml 699 701 699 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 701 703 701 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pz</italic>
###xml 701 703 701 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>pz</italic></sup>
###xml 704 706 704 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 706 707 706 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 706 707 706 707 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></sup>
###xml 499 503 <span type="species:ncbi:10090">mice</span>
Males and females of strains O20/A (abbrev. O20), OcB-9/Dem (abbrev. OcB-9) (both strains have the MHC haplotype H2pz) and F2 hybrids between O20 and OcB-9 came from P. Demant's breeding colony. The haplotype H2pz is described in [26]. The genetic composition of strain OcB-9 has been described in detail by Stassen and co-workers [27]. When used for these experiments strain OcB-9 passed more than 31 generations of brother-sister mating and was highly homozygous. C57BL/10SnPh (abbrev. B10) (H2b) mice were from the Institute of Molecular Genetics (Prague). As the strains O20 and OcB-9 are MHC identical, all mixed lymphocyte reactions tested in this paper involved the same MHC incompatibility (H2pz-H2b).
###end p 12
###begin title 13
Mixed lymphocyte culture
###end title 13
###begin p 14
###xml 47 48 47 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 68 69 68 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 108 109 108 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 270 272 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 406 407 399 400 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 56 60 <span type="species:ncbi:10090">mice</span>
###xml 408 412 <span type="species:ncbi:10090">mice</span>
###xml 453 457 <span type="species:ncbi:10090">mice</span>
Spleen cells of O20, OcB-9, and of individual F2 hybrid mice (6 x 105 cells per well) were mixed with 8 x 105 irradiated (3000 R) C57BL/10 stimulator cells in 800 mul in 24-well tissue culture plates in complete RPMI 1640 medium, respectively (Nunc, Roskilde, Denmark) [28]. Supernatants were removed after 96 h incubation period and stored at -70degreesC before use. Each day in a separate experiment 20 F2 mice and appropriate controls (O20 and OcB-9 mice) were tested. In the experiments, comparing IFNgamma, IL-2, and IL-4 production by stimulated lymphocytes of strains O20 and OcB-9, supernatants were removed also 48 and 72 h after stimulation.
###end p 14
###begin title 15
Concanavalin A-stimulated cultures
###end title 15
###begin p 16
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
Spleen cells (4 x 105 cells per well) were incubated in 800 mul in 24-well tissue culture plates in complete RPMI 1640 medium with 2.5 mug/ml ConA. Supernatants were collected after 24, 48, or 72 h of incubation and assayed for IFNgamma presence.
###end p 16
###begin title 17
Estimation of cytokine levels
###end title 17
###begin p 18
###xml 542 543 529 530 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1190 1191 1164 1165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1192 1193 1166 1167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 931 942 <span type="species:ncbi:3704">horseradish</span>
Supernatants from MLR cultures were assayed for IFNgamma, IL-2, and IL-4 presence using the primary and secondary mAbs (R46A2, XMG1.2; JES6-1A11, JES6-5H4; 11B11, BVD6-24G2) and standards (mIFNgamma, mIL-2, and mIL-4) from BD Bioscience, San Jose, CA. Similarly, supernatants from ConA stimulated cultures were assayed for IFNgamma. The ELISA was performed using the conditions recommended by BD Bioscience. In brief, a 96-well flatbottom plate (Costar, Cambridge, MA) was coated with primary mAb at a concentration of 1 mug/ml in 0.1 M NaHCO3 pH 8.2 and incubated overnight at 4degreesC. The plates were washed with PBS-Tween (Costar, Corning, NY) and incubated for 2 h with 200 mul of PBS 8% BSA. After washing, aliquots of supernatants were added to duplicate wells and incubated overnight at 4degreesC. Plates were washed again and biotin-labeled secondary mAb was added for 45 min. Plates were washed, followed by addition of horseradish peroxidase streptavidin (Vector Laboratories, Burlingame, CA). 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (Sigma-Aldrich, St. Louis, MO) and peroxide were used as chromogen. Color reaction was stopped by sodium dodecyl sulfate (SDS) in N,N-dimethylformamide and plates were read at OD 405 nm and the IFNgamma levels were estimated by the ELISA reader Tecan and the curve fitter program KIM-E (Schoeller Pharma, Prague, Czech Republic) using least square nonlinear regression analysis. Sensitivity of detection of IFNgamma, IL-2, and IL-4 levels in supernatants was 32, 4, and 15 pg/ml, respectively.
###end p 18
###begin title 19
Genotyping of microsatellites by PCR
###end title 19
###begin p 20
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 209 210 209 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 633 634 633 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">o</italic>
###xml 672 673 672 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 719 721 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 913 915 907 909 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 218 222 <span type="species:ncbi:10090">mice</span>
DNA was isolated from tails using a standard proteinase procedure. The strain OcB-9 differs from O20 by carrying B10.O20-derived segments at 10 chromosomes [27]. These differential segments were typed in the F2 hybrid mice using 15 microsatellite markers: D2Mit7, D2Mit56; D4Mit54; D6Mit31, D6Mit52; D7Mit12, D7Nds2; D8Mit3, D8Mit65; D10Mit12; D11Mit15; D16Mit130; D18Mit17; D19Mit3, D19Mit63. These markers were selected because they cover optimally the chromosomal segments at which the OcB-9 strain has genetic material from the B10.O20 strain. They carry different alleles in the two parental strains, the O20 allele (designated o), and the B10.O20 allele (designated b). PCR genotyping was performed as described [29]. Briefly, amplification was performed with a MJ Research Thermal Cycler PTC 100 Model 96 (MJ Research, Watertown, MA) in a volume of 10 mul with 20 ng DNA, 0.23 muM of forward primer [gamma-32P]ATP end-labeled with T4 polynucleotide kinase (New England Biolabs, Schwalbach, Germany), 0.23 muM of reverse primer, 200 muM of each dNTP and 0.04 u Taq polymerase (GIBCO, Grand Island, NY) in a 96-well U-bottom microtiter plate (FALCON, Oxford, UK) with 1 cycle of 3 min at 94degreesC and 30 cycles of 30 s at 94degreesC, 1 min at 55degreesC and 1 min at 72degreesC and 1 cycle of 1 min at 55degreesC, 3 min at 72degreesC, and 1 min at 23degreesC. Each PCR product was mixed with 30 mul of loading buffer and electrophoresed in 6% acrylamide gels for 2-2.5 h at 50 W. Gels were wrapped in Saran Wrap (Dow Chemicals Co., Midland, MI) and exposed to X-ray film X-OMAT AR (Kodak, Weesp, The Netherlands) for 1.5-24 h at -70degreesC.
###end p 20
###begin title 21
Statistical analysis
###end title 21
###begin p 22
###xml 423 425 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 511 512 503 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 523 524 515 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 589 590 581 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 781 782 773 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 791 793 783 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pc</italic>
###xml 801 802 789 790 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T</sub>
###xml 853 855 841 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 880 881 868 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 955 956 943 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1028 1029 1014 1015 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1043 1044 1029 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">h</italic>
###xml 1045 1046 1031 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 1075 1076 1061 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
The role of genetic factors in IFNgamma production in MLR response was examined by analysis of variance [ANOVA, PROC GLM statement of the SAS 8.2 for Windows (SAS Institute, Cary, NC)]. The effect of each marker, sex, and experiment on IFNgamma level in supernatants was tested. Each individual marker and its interactions with other markers and sex or experiment were subjected to ANOVA. A backward elimination procedure [30] was followed wherein the interaction of marker (or interaction) bearing the highest P value (if P > 0.05) was eliminated first. The markers and interactions with P value smaller than 0.05 were pooled for the next round of ANOVA. The backward elimination procedure was repeated till the final set of significant markers and interactions was obtained. The P values (Pc = alphaT) were corrected according to Lander and Kruglyak [31] using the formula:with G = 2 M (the length of the segregating part of the genome: 12.5% of 16 M); C = 10 (number of chromosomes segregating in this cross); rho = 1.5 for F2 hybrids; and h(T) = the observed statistics (F ratio).
###end p 22
###begin p 23
###xml 116 117 112 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
IFNgamma, IL-2, and IL-4 production in MLR by cells of responder strains O20 and OcB-9 was compared by Mann-Whitney U test (STATISTICA for Windows 5.0, StatSoft, Inc., Tulsa, OK).
###end p 23
###begin title 24
Results
###end title 24
###begin title 25
Strain differences in proliferation and production of cytokines after stimulation with alloantigen or ConA
###end title 25
###begin p 26
###xml 118 120 118 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 120 122 120 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pz</italic>
###xml 120 122 120 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>pz</italic></sup>
###xml 185 187 185 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 187 188 187 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 187 188 187 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></sup>
###xml 202 204 202 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 204 205 204 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 204 205 204 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>d</italic></sup>
###xml 217 219 217 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 219 220 219 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 219 220 219 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>k</italic></sup>
###xml 264 265 264 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 516 518 512 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 518 519 514 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 518 519 514 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></sup>
###xml 533 534 529 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 549 551 545 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 551 552 547 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 551 552 547 548 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>d</italic></sup>
###xml 612 614 608 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 614 615 610 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">q</italic>
###xml 614 615 610 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>q</italic></sup>
###xml 626 628 622 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 628 629 624 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 628 629 624 625 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>k</italic></sup>
###xml 637 638 633 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 753 754 745 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 825 826 817 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 851 852 843 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 899 905 891 897 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1049 1051 1041 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 1051 1052 1043 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1051 1052 1043 1044 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></sup>
###xml 1069 1071 1061 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 1071 1072 1063 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 1071 1072 1063 1064 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>d</italic></sup>
###xml 1087 1089 1079 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 1089 1090 1081 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 1089 1090 1081 1082 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>k</italic></sup>
###xml 1128 1129 1120 1121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 1168 1169 1160 1161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 1405 1407 1395 1397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 1523 1525 1511 1513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 905 1526 897 1514 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27">The MLC reactivity of O20, B10.O20, and OcB-9 strains. Proliferative response of spleen cells in RPMI medium only and stimulated by C57BL/10Sn (<italic>H2</italic><sup><italic>b</italic></sup>) (B10), BALB/c (<italic>H2</italic><sup><italic>d</italic></sup>), and CBA/Ph (<italic>H2</italic><sup><italic>k</italic></sup>) alloantigens. Spleen cells (1.5&#160;&#215;&#160;10<sup>5</sup> cells per well) were mixed with 2&#160;&#215;&#160;10<sup>5</sup> irradiated (3000 R) B10, BALB/c or CBA/Ph stimulator cells in 200&#160;&#956;l in 96-well tissue culture plates. [3H]-thymidine (0.5&#160;&#956;Ci/well) was added into the cultures for the last 6&#160;h of the 96-h incubation period as described previously [<xref ref-type="bibr" rid="CR17">17</xref>]. The data show the mean&#160;&#177;&#160;SE from three independent experiments. Reproduced with the kind permission from Ref. [<xref ref-type="bibr" rid="CR17">17</xref>]</p>
###xml 905 1526 897 1514 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="27">The MLC reactivity of O20, B10.O20, and OcB-9 strains. Proliferative response of spleen cells in RPMI medium only and stimulated by C57BL/10Sn (<italic>H2</italic><sup><italic>b</italic></sup>) (B10), BALB/c (<italic>H2</italic><sup><italic>d</italic></sup>), and CBA/Ph (<italic>H2</italic><sup><italic>k</italic></sup>) alloantigens. Spleen cells (1.5&#160;&#215;&#160;10<sup>5</sup> cells per well) were mixed with 2&#160;&#215;&#160;10<sup>5</sup> irradiated (3000 R) B10, BALB/c or CBA/Ph stimulator cells in 200&#160;&#956;l in 96-well tissue culture plates. [3H]-thymidine (0.5&#160;&#956;Ci/well) was added into the cultures for the last 6&#160;h of the 96-h incubation period as described previously [<xref ref-type="bibr" rid="CR17">17</xref>]. The data show the mean&#160;&#177;&#160;SE from three independent experiments. Reproduced with the kind permission from Ref. [<xref ref-type="bibr" rid="CR17">17</xref>]</p></caption>
###xml 1526 1526 1514 1514 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="262_2009_739_Fig1_HTML" id="MO2"/>
###xml 899 1526 891 1514 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="27">The MLC reactivity of O20, B10.O20, and OcB-9 strains. Proliferative response of spleen cells in RPMI medium only and stimulated by C57BL/10Sn (<italic>H2</italic><sup><italic>b</italic></sup>) (B10), BALB/c (<italic>H2</italic><sup><italic>d</italic></sup>), and CBA/Ph (<italic>H2</italic><sup><italic>k</italic></sup>) alloantigens. Spleen cells (1.5&#160;&#215;&#160;10<sup>5</sup> cells per well) were mixed with 2&#160;&#215;&#160;10<sup>5</sup> irradiated (3000 R) B10, BALB/c or CBA/Ph stimulator cells in 200&#160;&#956;l in 96-well tissue culture plates. [3H]-thymidine (0.5&#160;&#956;Ci/well) was added into the cultures for the last 6&#160;h of the 96-h incubation period as described previously [<xref ref-type="bibr" rid="CR17">17</xref>]. The data show the mean&#160;&#177;&#160;SE from three independent experiments. Reproduced with the kind permission from Ref. [<xref ref-type="bibr" rid="CR17">17</xref>]</p></caption><graphic position="anchor" xlink:href="262_2009_739_Fig1_HTML" id="MO2"/></fig>
###xml 1526 1532 1514 1520 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1532 1533 1520 1521 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1690 1691 1674 1675 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 1730 1731 1714 1715 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 2130 2143 2107 2120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Filled square</italic>
###xml 2152 2167 2129 2144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">unfilled square</italic>
###xml 2174 2175 2151 2152 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2314 2316 2287 2289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 2316 2317 2289 2290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 2316 2317 2289 2290 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></sup>
###xml 2328 2330 2301 2303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 2330 2331 2303 2304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 2330 2331 2303 2304 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>d</italic></sup>
###xml 2339 2341 2312 2314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 2341 2342 2314 2315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 2341 2342 2314 2315 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>k</italic></sup>
###xml 2356 2358 2329 2331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 2358 2359 2331 2332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">q</italic>
###xml 2358 2359 2331 2332 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>q</italic></sup>
###xml 2395 2396 2368 2369 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 2435 2436 2408 2409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 1532 2671 1520 2643 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28"><bold>a</bold> Comparison of concentration of IFN&#947; in supernatants of the spleen cells of the strains OcB-9 and O20 after alloantigen stimulation. Spleen cells (6&#160;&#215;&#160;10<sup>5</sup> cells per well) were mixed with 8&#160;&#215;&#160;10<sup>5</sup> irradiated (3000 R) C57BL/10 stimulator cells in 800&#160;&#956;l in 24-well tissue culture plates. Cell supernatants were analyzed 48, 72, and 96&#160;h after stimulation. Data summarize the result of 13 independent experiments. Both female and male mice were used in our analysis, but no influence of sex on strain difference was observed. The columns show the means&#160;&#177;&#160;SE of IFN&#947; concentration in ng/ml. <italic>Filled square</italic>: OcB-9, <italic>unfilled square</italic>: O20. <bold>b</bold> Comparison of concentration of IFN&#947; in supernatants of the spleen cells of the strains OcB-9 and O20 after stimulation by C57BL/10Sn (<italic>H2</italic><sup><italic>b</italic></sup>), BALB/c (<italic>H2</italic><sup><italic>d</italic></sup>), CBA (<italic>H2</italic><sup><italic>k</italic></sup>), and DBA/1 (<italic>H2</italic><sup><italic>q</italic></sup>) alloantigens. Spleen cells (6&#160;&#215;&#160;10<sup>5</sup> cells per well) were mixed with 8&#160;&#215;&#160;10<sup>5</sup> irradiated (3000 R) C57BL/10Sn, BALB/c, CBA, or DBA/1 stimulator cells in 800&#160;&#956;l in 24-well tissue culture plates. Cell supernatants were analysed 72 and 96&#160;h after stimulation. Data summarize the result of 13 independent experiments</p>
###xml 1532 2671 1520 2643 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28"><bold>a</bold> Comparison of concentration of IFN&#947; in supernatants of the spleen cells of the strains OcB-9 and O20 after alloantigen stimulation. Spleen cells (6&#160;&#215;&#160;10<sup>5</sup> cells per well) were mixed with 8&#160;&#215;&#160;10<sup>5</sup> irradiated (3000 R) C57BL/10 stimulator cells in 800&#160;&#956;l in 24-well tissue culture plates. Cell supernatants were analyzed 48, 72, and 96&#160;h after stimulation. Data summarize the result of 13 independent experiments. Both female and male mice were used in our analysis, but no influence of sex on strain difference was observed. The columns show the means&#160;&#177;&#160;SE of IFN&#947; concentration in ng/ml. <italic>Filled square</italic>: OcB-9, <italic>unfilled square</italic>: O20. <bold>b</bold> Comparison of concentration of IFN&#947; in supernatants of the spleen cells of the strains OcB-9 and O20 after stimulation by C57BL/10Sn (<italic>H2</italic><sup><italic>b</italic></sup>), BALB/c (<italic>H2</italic><sup><italic>d</italic></sup>), CBA (<italic>H2</italic><sup><italic>k</italic></sup>), and DBA/1 (<italic>H2</italic><sup><italic>q</italic></sup>) alloantigens. Spleen cells (6&#160;&#215;&#160;10<sup>5</sup> cells per well) were mixed with 8&#160;&#215;&#160;10<sup>5</sup> irradiated (3000 R) C57BL/10Sn, BALB/c, CBA, or DBA/1 stimulator cells in 800&#160;&#956;l in 24-well tissue culture plates. Cell supernatants were analysed 72 and 96&#160;h after stimulation. Data summarize the result of 13 independent experiments</p></caption>
###xml 2671 2671 2643 2643 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="262_2009_739_Fig2_HTML" id="MO3"/>
###xml 1526 2671 1514 2643 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="28"><bold>a</bold> Comparison of concentration of IFN&#947; in supernatants of the spleen cells of the strains OcB-9 and O20 after alloantigen stimulation. Spleen cells (6&#160;&#215;&#160;10<sup>5</sup> cells per well) were mixed with 8&#160;&#215;&#160;10<sup>5</sup> irradiated (3000 R) C57BL/10 stimulator cells in 800&#160;&#956;l in 24-well tissue culture plates. Cell supernatants were analyzed 48, 72, and 96&#160;h after stimulation. Data summarize the result of 13 independent experiments. Both female and male mice were used in our analysis, but no influence of sex on strain difference was observed. The columns show the means&#160;&#177;&#160;SE of IFN&#947; concentration in ng/ml. <italic>Filled square</italic>: OcB-9, <italic>unfilled square</italic>: O20. <bold>b</bold> Comparison of concentration of IFN&#947; in supernatants of the spleen cells of the strains OcB-9 and O20 after stimulation by C57BL/10Sn (<italic>H2</italic><sup><italic>b</italic></sup>), BALB/c (<italic>H2</italic><sup><italic>d</italic></sup>), CBA (<italic>H2</italic><sup><italic>k</italic></sup>), and DBA/1 (<italic>H2</italic><sup><italic>q</italic></sup>) alloantigens. Spleen cells (6&#160;&#215;&#160;10<sup>5</sup> cells per well) were mixed with 8&#160;&#215;&#160;10<sup>5</sup> irradiated (3000 R) C57BL/10Sn, BALB/c, CBA, or DBA/1 stimulator cells in 800&#160;&#956;l in 24-well tissue culture plates. Cell supernatants were analysed 72 and 96&#160;h after stimulation. Data summarize the result of 13 independent experiments</p></caption><graphic position="anchor" xlink:href="262_2009_739_Fig2_HTML" id="MO3"/></fig>
###xml 2671 2677 2643 2649 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 2885 2886 2847 2848 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 3230 3236 3181 3187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Square</italic>
###xml 3245 3260 3196 3211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">unfilled square</italic>
###xml 2677 3265 2649 3216 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29">Comparison of concentration of IFN&#947; in supernatants of the spleen cells of the strains OcB-9 and O20 after stimulation with 2.5&#160;&#956;g/ml ConA. To test IFN&#947; concentration, 800&#160;&#956;l of spleen cells (4&#160;&#215;&#160;10<sup>5</sup> cells per well) were incubated in 24-well tissue culture plates in complete RPMI 1640 medium with 2.5&#160;&#956;g/ml ConA. After 24, 48, or 72&#160;h of incubation supernatants were collected and assayed for IFN&#947; presence. The columns show the means&#160;&#177;&#160;SE of IFN&#947; concentration in ng/ml. Data summarize the result of four independent experiments. <italic>Square</italic>: OcB-9, <italic>unfilled square</italic>: O20</p>
###xml 2677 3265 2649 3216 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29">Comparison of concentration of IFN&#947; in supernatants of the spleen cells of the strains OcB-9 and O20 after stimulation with 2.5&#160;&#956;g/ml ConA. To test IFN&#947; concentration, 800&#160;&#956;l of spleen cells (4&#160;&#215;&#160;10<sup>5</sup> cells per well) were incubated in 24-well tissue culture plates in complete RPMI 1640 medium with 2.5&#160;&#956;g/ml ConA. After 24, 48, or 72&#160;h of incubation supernatants were collected and assayed for IFN&#947; presence. The columns show the means&#160;&#177;&#160;SE of IFN&#947; concentration in ng/ml. Data summarize the result of four independent experiments. <italic>Square</italic>: OcB-9, <italic>unfilled square</italic>: O20</p></caption>
###xml 3265 3265 3216 3216 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="262_2009_739_Fig3_HTML" id="MO4"/>
###xml 2671 3265 2643 3216 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="29">Comparison of concentration of IFN&#947; in supernatants of the spleen cells of the strains OcB-9 and O20 after stimulation with 2.5&#160;&#956;g/ml ConA. To test IFN&#947; concentration, 800&#160;&#956;l of spleen cells (4&#160;&#215;&#160;10<sup>5</sup> cells per well) were incubated in 24-well tissue culture plates in complete RPMI 1640 medium with 2.5&#160;&#956;g/ml ConA. After 24, 48, or 72&#160;h of incubation supernatants were collected and assayed for IFN&#947; presence. The columns show the means&#160;&#177;&#160;SE of IFN&#947; concentration in ng/ml. Data summarize the result of four independent experiments. <italic>Square</italic>: OcB-9, <italic>unfilled square</italic>: O20</p></caption><graphic position="anchor" xlink:href="262_2009_739_Fig3_HTML" id="MO4"/></fig>
###xml 3265 3271 3216 3222 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 3271 3272 3222 3223 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 3425 3426 3376 3377 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 3465 3466 3416 3417 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 3861 3874 3809 3822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Filled square</italic>
###xml 3883 3898 3831 3846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">unfilled square</italic>
###xml 3905 3906 3853 3854 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 4059 4060 4007 4008 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 4099 4100 4047 4048 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 4495 4508 4440 4453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Filled square</italic>
###xml 4517 4532 4462 4477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">unfilled square</italic>
###xml 3271 4537 3222 4482 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30"><bold>a</bold> Comparison of concentration of IL-2 in supernatants of the spleen cells of the strains OcB-9 and O20 after alloantigen stimulation. Spleen cells (6&#160;&#215;&#160;10<sup>5</sup> cells per well) were mixed with 8&#160;&#215;&#160;10<sup>5</sup> irradiated (3000 R) C57BL/10 stimulator cells in 800 &#956;l in 24-well tissue culture plates. Cell supernatants were analysed 48, 72, and 96&#160;h after stimulation. Data summarize the result of 13 independent experiments. Both female and male mice were used in our analysis, but no influence of sex on strain difference was observed. The columns show the means&#160;&#177;&#160;SE of IL-2 concentration in ng/ml. <italic>Filled square</italic>: OcB-9, <italic>unfilled square</italic>: O20. <bold>b</bold> Comparison of concentration of IL-4 in supernatants of the spleen cells of the strains OcB-9 and O20 after alloantigen stimulation. Spleen cells (6&#160;&#215;&#160;10<sup>5</sup> cells per well) were mixed with 8&#160;&#215;&#160;10<sup>5</sup> irradiated (3000 R) C57BL/10 stimulator cells in 800&#160;&#956;l in 24-well tissue culture plates. Cell supernatants were analysed 48, 72, and 96&#160;h after stimulation. Data summarize the result of 13 independent experiments. Both female and male mice were used in our analysis, but no influence of sex on strain difference was observed. The columns show the means&#160;&#177;&#160;SE of IL-4 concentration in ng/ml. <italic>Filled square</italic>: OcB-9, <italic>unfilled square</italic>: O20</p>
###xml 3271 4537 3222 4482 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30"><bold>a</bold> Comparison of concentration of IL-2 in supernatants of the spleen cells of the strains OcB-9 and O20 after alloantigen stimulation. Spleen cells (6&#160;&#215;&#160;10<sup>5</sup> cells per well) were mixed with 8&#160;&#215;&#160;10<sup>5</sup> irradiated (3000 R) C57BL/10 stimulator cells in 800 &#956;l in 24-well tissue culture plates. Cell supernatants were analysed 48, 72, and 96&#160;h after stimulation. Data summarize the result of 13 independent experiments. Both female and male mice were used in our analysis, but no influence of sex on strain difference was observed. The columns show the means&#160;&#177;&#160;SE of IL-2 concentration in ng/ml. <italic>Filled square</italic>: OcB-9, <italic>unfilled square</italic>: O20. <bold>b</bold> Comparison of concentration of IL-4 in supernatants of the spleen cells of the strains OcB-9 and O20 after alloantigen stimulation. Spleen cells (6&#160;&#215;&#160;10<sup>5</sup> cells per well) were mixed with 8&#160;&#215;&#160;10<sup>5</sup> irradiated (3000 R) C57BL/10 stimulator cells in 800&#160;&#956;l in 24-well tissue culture plates. Cell supernatants were analysed 48, 72, and 96&#160;h after stimulation. Data summarize the result of 13 independent experiments. Both female and male mice were used in our analysis, but no influence of sex on strain difference was observed. The columns show the means&#160;&#177;&#160;SE of IL-4 concentration in ng/ml. <italic>Filled square</italic>: OcB-9, <italic>unfilled square</italic>: O20</p></caption>
###xml 4537 4537 4482 4482 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="262_2009_739_Fig4_HTML" id="MO5"/>
###xml 3265 4537 3216 4482 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="30"><bold>a</bold> Comparison of concentration of IL-2 in supernatants of the spleen cells of the strains OcB-9 and O20 after alloantigen stimulation. Spleen cells (6&#160;&#215;&#160;10<sup>5</sup> cells per well) were mixed with 8&#160;&#215;&#160;10<sup>5</sup> irradiated (3000 R) C57BL/10 stimulator cells in 800 &#956;l in 24-well tissue culture plates. Cell supernatants were analysed 48, 72, and 96&#160;h after stimulation. Data summarize the result of 13 independent experiments. Both female and male mice were used in our analysis, but no influence of sex on strain difference was observed. The columns show the means&#160;&#177;&#160;SE of IL-2 concentration in ng/ml. <italic>Filled square</italic>: OcB-9, <italic>unfilled square</italic>: O20. <bold>b</bold> Comparison of concentration of IL-4 in supernatants of the spleen cells of the strains OcB-9 and O20 after alloantigen stimulation. Spleen cells (6&#160;&#215;&#160;10<sup>5</sup> cells per well) were mixed with 8&#160;&#215;&#160;10<sup>5</sup> irradiated (3000 R) C57BL/10 stimulator cells in 800&#160;&#956;l in 24-well tissue culture plates. Cell supernatants were analysed 48, 72, and 96&#160;h after stimulation. Data summarize the result of 13 independent experiments. Both female and male mice were used in our analysis, but no influence of sex on strain difference was observed. The columns show the means&#160;&#177;&#160;SE of IL-4 concentration in ng/ml. <italic>Filled square</italic>: OcB-9, <italic>unfilled square</italic>: O20</p></caption><graphic position="anchor" xlink:href="262_2009_739_Fig4_HTML" id="MO5"/></fig>
###xml 1969 1973 <span type="species:ncbi:10090">mice</span>
###xml 3704 3708 <span type="species:ncbi:10090">mice</span>
###xml 4338 4342 <span type="species:ncbi:10090">mice</span>
The proliferation of lymphocytes of the strain OcB-9 in MLC is higher than that of the MHC-identical strain O20 (both H2pz) after stimulation with lymphocytes of strains with C57BL/10 (H2b), BALB/cHeA (H2d), and CBA (H2k) that carry unrelated MHC haplotypes (Fig. 1 and Ref. 17). This indicates that strain OcB-9 has a higher propensity to respond to a variety of alloantigens than O20. The production of IFNgamma in MLC is also significantly higher by OcB-9 than by O20 responder cells when stimulated by C57BL/10 (H2b) cells (Fig. 2a) and BALB/c (H2d) cells, but it is low in both with weaker stimulators DBA (H2q) and CBA (H2k) (Fig. 2b). OcB-9 lymphocytes are also better producers of IFNgamma than O20 lymphocytes after stimulation with ConA (Fig. 3). In MLC with C57BL/10 stimulator cells, the production of IL-2 (Fig. 4a) but not of IL-4 (Fig. 4b) is higher by OcB-9 than O20 responder cells.Fig. 1The MLC reactivity of O20, B10.O20, and OcB-9 strains. Proliferative response of spleen cells in RPMI medium only and stimulated by C57BL/10Sn (H2b) (B10), BALB/c (H2d), and CBA/Ph (H2k) alloantigens. Spleen cells (1.5 x 105 cells per well) were mixed with 2 x 105 irradiated (3000 R) B10, BALB/c or CBA/Ph stimulator cells in 200 mul in 96-well tissue culture plates. [3H]-thymidine (0.5 muCi/well) was added into the cultures for the last 6 h of the 96-h incubation period as described previously [17]. The data show the mean +/- SE from three independent experiments. Reproduced with the kind permission from Ref. [17]Fig. 2a Comparison of concentration of IFNgamma in supernatants of the spleen cells of the strains OcB-9 and O20 after alloantigen stimulation. Spleen cells (6 x 105 cells per well) were mixed with 8 x 105 irradiated (3000 R) C57BL/10 stimulator cells in 800 mul in 24-well tissue culture plates. Cell supernatants were analyzed 48, 72, and 96 h after stimulation. Data summarize the result of 13 independent experiments. Both female and male mice were used in our analysis, but no influence of sex on strain difference was observed. The columns show the means +/- SE of IFNgamma concentration in ng/ml. Filled square: OcB-9, unfilled square: O20. b Comparison of concentration of IFNgamma in supernatants of the spleen cells of the strains OcB-9 and O20 after stimulation by C57BL/10Sn (H2b), BALB/c (H2d), CBA (H2k), and DBA/1 (H2q) alloantigens. Spleen cells (6 x 105 cells per well) were mixed with 8 x 105 irradiated (3000 R) C57BL/10Sn, BALB/c, CBA, or DBA/1 stimulator cells in 800 mul in 24-well tissue culture plates. Cell supernatants were analysed 72 and 96 h after stimulation. Data summarize the result of 13 independent experimentsFig. 3Comparison of concentration of IFNgamma in supernatants of the spleen cells of the strains OcB-9 and O20 after stimulation with 2.5 mug/ml ConA. To test IFNgamma concentration, 800 mul of spleen cells (4 x 105 cells per well) were incubated in 24-well tissue culture plates in complete RPMI 1640 medium with 2.5 mug/ml ConA. After 24, 48, or 72 h of incubation supernatants were collected and assayed for IFNgamma presence. The columns show the means +/- SE of IFNgamma concentration in ng/ml. Data summarize the result of four independent experiments. Square: OcB-9, unfilled square: O20Fig. 4a Comparison of concentration of IL-2 in supernatants of the spleen cells of the strains OcB-9 and O20 after alloantigen stimulation. Spleen cells (6 x 105 cells per well) were mixed with 8 x 105 irradiated (3000 R) C57BL/10 stimulator cells in 800 mul in 24-well tissue culture plates. Cell supernatants were analysed 48, 72, and 96 h after stimulation. Data summarize the result of 13 independent experiments. Both female and male mice were used in our analysis, but no influence of sex on strain difference was observed. The columns show the means +/- SE of IL-2 concentration in ng/ml. Filled square: OcB-9, unfilled square: O20. b Comparison of concentration of IL-4 in supernatants of the spleen cells of the strains OcB-9 and O20 after alloantigen stimulation. Spleen cells (6 x 105 cells per well) were mixed with 8 x 105 irradiated (3000 R) C57BL/10 stimulator cells in 800 mul in 24-well tissue culture plates. Cell supernatants were analysed 48, 72, and 96 h after stimulation. Data summarize the result of 13 independent experiments. Both female and male mice were used in our analysis, but no influence of sex on strain difference was observed. The columns show the means +/- SE of IL-4 concentration in ng/ml. Filled square: OcB-9, unfilled square: O20
###end p 26
###begin p 27
###xml 144 146 144 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 146 147 146 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 146 147 146 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></sup>
###xml 164 166 164 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 166 167 166 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 166 167 166 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>d</italic></sup>
###xml 182 184 182 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 184 185 184 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 184 185 184 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>k</italic></sup>
###xml 223 224 223 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 263 264 263 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 500 502 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 618 620 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
The MLC reactivity of O20, B10.O20, and OcB-9 strains. Proliferative response of spleen cells in RPMI medium only and stimulated by C57BL/10Sn (H2b) (B10), BALB/c (H2d), and CBA/Ph (H2k) alloantigens. Spleen cells (1.5 x 105 cells per well) were mixed with 2 x 105 irradiated (3000 R) B10, BALB/c or CBA/Ph stimulator cells in 200 mul in 96-well tissue culture plates. [3H]-thymidine (0.5 muCi/well) was added into the cultures for the last 6 h of the 96-h incubation period as described previously [17]. The data show the mean +/- SE from three independent experiments. Reproduced with the kind permission from Ref. [17]
###end p 27
###begin p 28
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 158 159 154 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 198 199 194 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 598 611 587 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Filled square</italic>
###xml 620 635 609 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">unfilled square</italic>
###xml 642 643 631 632 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 782 784 767 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 784 785 769 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 784 785 769 770 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></sup>
###xml 796 798 781 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 798 799 783 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 798 799 783 784 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>d</italic></sup>
###xml 807 809 792 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 809 810 794 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 809 810 794 795 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>k</italic></sup>
###xml 824 826 809 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 826 827 811 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">q</italic>
###xml 826 827 811 812 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>q</italic></sup>
###xml 863 864 848 849 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 903 904 888 889 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 437 441 <span type="species:ncbi:10090">mice</span>
a Comparison of concentration of IFNgamma in supernatants of the spleen cells of the strains OcB-9 and O20 after alloantigen stimulation. Spleen cells (6 x 105 cells per well) were mixed with 8 x 105 irradiated (3000 R) C57BL/10 stimulator cells in 800 mul in 24-well tissue culture plates. Cell supernatants were analyzed 48, 72, and 96 h after stimulation. Data summarize the result of 13 independent experiments. Both female and male mice were used in our analysis, but no influence of sex on strain difference was observed. The columns show the means +/- SE of IFNgamma concentration in ng/ml. Filled square: OcB-9, unfilled square: O20. b Comparison of concentration of IFNgamma in supernatants of the spleen cells of the strains OcB-9 and O20 after stimulation by C57BL/10Sn (H2b), BALB/c (H2d), CBA (H2k), and DBA/1 (H2q) alloantigens. Spleen cells (6 x 105 cells per well) were mixed with 8 x 105 irradiated (3000 R) C57BL/10Sn, BALB/c, CBA, or DBA/1 stimulator cells in 800 mul in 24-well tissue culture plates. Cell supernatants were analysed 72 and 96 h after stimulation. Data summarize the result of 13 independent experiments
###end p 28
###begin p 29
###xml 208 209 198 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 553 559 532 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Square</italic>
###xml 568 583 547 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">unfilled square</italic>
Comparison of concentration of IFNgamma in supernatants of the spleen cells of the strains OcB-9 and O20 after stimulation with 2.5 mug/ml ConA. To test IFNgamma concentration, 800 mul of spleen cells (4 x 105 cells per well) were incubated in 24-well tissue culture plates in complete RPMI 1640 medium with 2.5 mug/ml ConA. After 24, 48, or 72 h of incubation supernatants were collected and assayed for IFNgamma presence. The columns show the means +/- SE of IFNgamma concentration in ng/ml. Data summarize the result of four independent experiments. Square: OcB-9, unfilled square: O20
###end p 29
###begin p 30
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 154 155 154 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 194 195 194 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 590 603 587 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Filled square</italic>
###xml 612 627 609 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">unfilled square</italic>
###xml 634 635 631 632 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 788 789 785 786 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 828 829 825 826 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 1224 1237 1218 1231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Filled square</italic>
###xml 1246 1261 1240 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">unfilled square</italic>
###xml 433 437 <span type="species:ncbi:10090">mice</span>
###xml 1067 1071 <span type="species:ncbi:10090">mice</span>
a Comparison of concentration of IL-2 in supernatants of the spleen cells of the strains OcB-9 and O20 after alloantigen stimulation. Spleen cells (6 x 105 cells per well) were mixed with 8 x 105 irradiated (3000 R) C57BL/10 stimulator cells in 800 mul in 24-well tissue culture plates. Cell supernatants were analysed 48, 72, and 96 h after stimulation. Data summarize the result of 13 independent experiments. Both female and male mice were used in our analysis, but no influence of sex on strain difference was observed. The columns show the means +/- SE of IL-2 concentration in ng/ml. Filled square: OcB-9, unfilled square: O20. b Comparison of concentration of IL-4 in supernatants of the spleen cells of the strains OcB-9 and O20 after alloantigen stimulation. Spleen cells (6 x 105 cells per well) were mixed with 8 x 105 irradiated (3000 R) C57BL/10 stimulator cells in 800 mul in 24-well tissue culture plates. Cell supernatants were analysed 48, 72, and 96 h after stimulation. Data summarize the result of 13 independent experiments. Both female and male mice were used in our analysis, but no influence of sex on strain difference was observed. The columns show the means +/- SE of IL-4 concentration in ng/ml. Filled square: OcB-9, unfilled square: O20
###end p 30
###begin title 31
Detection of loci that control IFNgamma level in MLC
###end title 31
###begin p 32
###xml 186 187 182 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 203 204 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 251 252 243 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 374 376 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 426 427 418 419 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 436 440 <span type="species:ncbi:10090">mice</span>
Supernatants of the spleen cells of the strain OcB-9 contain higher concentration of IFNgamma 96 h after stimulation with C57BL/10 cells than supernatants of spleen cells of strain O20 (P < 0.014) (Fig. 2a). We examined production of IFNgamma in 240 F2 hybrids between the strains O20 and OcB-9. The strains O20 and OcB-9 differ in their genetic material at 10 chromosomes [27]. These differential segments were typed in the F2 hybrids mice using 15 microsatellite markers listed above.
###end p 32
###begin p 33
###xml 112 113 108 109 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 281 286 277 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr4</italic>
###xml 340 341 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 363 368 359 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr5</italic>
###xml 398 399 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 560 561 552 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 660 665 652 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr4</italic>
###xml 667 669 659 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">oo</italic>
###xml 766 768 754 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bb</italic>
###xml 814 819 802 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr5</italic>
###xml 989 990 977 978 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1002 1005 990 993 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;24</sup>
###xml 1090 1097 1078 1085 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1129 1134 1117 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr4</italic>
###xml 1139 1144 1127 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr5</italic>
###xml 1225 1226 1209 1210 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1097 1297 1085 1281 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34">Effects of genotype at the loci <italic>Cypr4</italic> and <italic>Cypr5</italic> on the concentration of IFN&#947; in supernatants of spleen cells of individual F<sub>2</sub> hybrids between OcB-9 and O20 stimulated by irradiated B10 splenocytes</p>
###xml 1097 1297 1085 1281 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="34">Effects of genotype at the loci <italic>Cypr4</italic> and <italic>Cypr5</italic> on the concentration of IFN&#947; in supernatants of spleen cells of individual F<sub>2</sub> hybrids between OcB-9 and O20 stimulated by irradiated B10 splenocytes</p></caption>
###xml 1297 1309 1281 1293 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Marker/locus</th>
###xml 1309 1317 1293 1301 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">Genotype</th>
###xml 1317 1318 1301 1302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1317 1324 1301 1308 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"><italic>P</italic> value</th>
###xml 1334 1335 1318 1319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1324 1335 1308 1319 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Corrected <italic>P</italic></th>
###xml 1297 1335 1281 1319 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2">Marker/locus</th><th align="left" colspan="3">Genotype</th><th align="left" rowspan="2"><italic>P</italic> value</th><th align="left" rowspan="2">Corrected <italic>P</italic></th></tr>
###xml 1335 1337 1319 1321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">oo</italic>
###xml 1335 1337 1319 1321 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>oo</italic></th>
###xml 1337 1339 1321 1323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob</italic>
###xml 1337 1339 1321 1323 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>ob</italic></th>
###xml 1339 1341 1323 1325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bb</italic>
###xml 1339 1341 1323 1325 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>bb</italic></th>
###xml 1335 1341 1319 1325 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"><italic>oo</italic></th><th align="left"><italic>ob</italic></th><th align="left"><italic>bb</italic></th></tr>
###xml 1297 1341 1281 1325 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="2">Marker/locus</th><th align="left" colspan="3">Genotype</th><th align="left" rowspan="2"><italic>P</italic> value</th><th align="left" rowspan="2">Corrected <italic>P</italic></th></tr><tr><th align="left"><italic>oo</italic></th><th align="left"><italic>ob</italic></th><th align="left"><italic>bb</italic></th></tr></thead>
###xml 1350 1355 1334 1339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr4</italic>
###xml 1341 1356 1325 1340 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">D6Mit31 (<italic>Cypr4</italic>)</td>
###xml 1371 1372 1353 1354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1356 1378 1340 1360 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7.74&#160;&#177;&#160;0.60 (<italic>n</italic>&#160;=&#160;64)</td>
###xml 1393 1394 1373 1374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1378 1401 1360 1381 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5.77&#160;&#177;&#160;0.47 (<italic>n</italic>&#160;=&#160;105)</td>
###xml 1416 1417 1394 1395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1401 1423 1381 1401 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.78&#160;&#177;&#160;0.69 (<italic>n</italic>&#160;=&#160;63)</td>
###xml 1423 1431 1401 1409 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.000100</td>
###xml 1431 1438 1409 1416 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.00717</td>
###xml 1341 1438 1325 1416 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">D6Mit31 (<italic>Cypr4</italic>)</td><td align="left">7.74&#160;&#177;&#160;0.60 (<italic>n</italic>&#160;=&#160;64)</td><td align="left">5.77&#160;&#177;&#160;0.47 (<italic>n</italic>&#160;=&#160;105)</td><td align="left">3.78&#160;&#177;&#160;0.69 (<italic>n</italic>&#160;=&#160;63)</td><td char="." align="char">0.000100</td><td char="." align="char">0.00717</td></tr>
###xml 1447 1452 1425 1430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr5</italic>
###xml 1438 1453 1416 1431 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">D6Mit52 (<italic>Cypr5</italic>)</td>
###xml 1468 1469 1444 1445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1453 1475 1431 1451 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.66&#160;&#177;&#160;0.74 (<italic>n</italic>&#160;=&#160;55)</td>
###xml 1490 1491 1464 1465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1475 1498 1451 1472 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5.09&#160;&#177;&#160;0.47 (<italic>n</italic>&#160;=&#160;121)</td>
###xml 1513 1514 1485 1486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1498 1520 1472 1492 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">9.43&#160;&#177;&#160;0.66 (<italic>n</italic>&#160;=&#160;63)</td>
###xml 1520 1530 1492 1502 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.00000296</td>
###xml 1530 1538 1502 1510 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.000257</td>
###xml 1438 1538 1416 1510 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">D6Mit52 (<italic>Cypr5</italic>)</td><td align="left">3.66&#160;&#177;&#160;0.74 (<italic>n</italic>&#160;=&#160;55)</td><td align="left">5.09&#160;&#177;&#160;0.47 (<italic>n</italic>&#160;=&#160;121)</td><td align="left">9.43&#160;&#177;&#160;0.66 (<italic>n</italic>&#160;=&#160;63)</td><td char="." align="char">0.00000296</td><td char="." align="char">0.000257</td></tr>
###xml 1341 1538 1325 1510 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">D6Mit31 (<italic>Cypr4</italic>)</td><td align="left">7.74&#160;&#177;&#160;0.60 (<italic>n</italic>&#160;=&#160;64)</td><td align="left">5.77&#160;&#177;&#160;0.47 (<italic>n</italic>&#160;=&#160;105)</td><td align="left">3.78&#160;&#177;&#160;0.69 (<italic>n</italic>&#160;=&#160;63)</td><td char="." align="char">0.000100</td><td char="." align="char">0.00717</td></tr><tr><td align="left">D6Mit52 (<italic>Cypr5</italic>)</td><td align="left">3.66&#160;&#177;&#160;0.74 (<italic>n</italic>&#160;=&#160;55)</td><td align="left">5.09&#160;&#177;&#160;0.47 (<italic>n</italic>&#160;=&#160;121)</td><td align="left">9.43&#160;&#177;&#160;0.66 (<italic>n</italic>&#160;=&#160;63)</td><td char="." align="char">0.00000296</td><td char="." align="char">0.000257</td></tr></tbody>
###xml 1297 1538 1281 1510 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Marker/locus</th><th align="left" colspan="3">Genotype</th><th align="left" rowspan="2"><italic>P</italic> value</th><th align="left" rowspan="2">Corrected <italic>P</italic></th></tr><tr><th align="left"><italic>oo</italic></th><th align="left"><italic>ob</italic></th><th align="left"><italic>bb</italic></th></tr></thead><tbody><tr><td align="left">D6Mit31 (<italic>Cypr4</italic>)</td><td align="left">7.74&#160;&#177;&#160;0.60 (<italic>n</italic>&#160;=&#160;64)</td><td align="left">5.77&#160;&#177;&#160;0.47 (<italic>n</italic>&#160;=&#160;105)</td><td align="left">3.78&#160;&#177;&#160;0.69 (<italic>n</italic>&#160;=&#160;63)</td><td char="." align="char">0.000100</td><td char="." align="char">0.00717</td></tr><tr><td align="left">D6Mit52 (<italic>Cypr5</italic>)</td><td align="left">3.66&#160;&#177;&#160;0.74 (<italic>n</italic>&#160;=&#160;55)</td><td align="left">5.09&#160;&#177;&#160;0.47 (<italic>n</italic>&#160;=&#160;121)</td><td align="left">9.43&#160;&#177;&#160;0.66 (<italic>n</italic>&#160;=&#160;63)</td><td char="." align="char">0.00000296</td><td char="." align="char">0.000257</td></tr></tbody></table>
###xml 1666 1674 1634 1642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brackets</italic>
###xml 1538 1845 1510 1809 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">The phenotypic values given for individual genotypes indicate mean and standard errors of the concentration of IFN&#947; and (in <italic>brackets</italic>) the number of mice (for computations the measured values of IFN&#947; in supernatants (ng/ml) were normalized by natural logarithm of (value&#160;+&#160;0.5) to the power of 0.005)</p>
###xml 1538 1845 1510 1809 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35">The phenotypic values given for individual genotypes indicate mean and standard errors of the concentration of IFN&#947; and (in <italic>brackets</italic>) the number of mice (for computations the measured values of IFN&#947; in supernatants (ng/ml) were normalized by natural logarithm of (value&#160;+&#160;0.5) to the power of 0.005)</p></table-wrap-foot>
###xml 1090 1845 1078 1809 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="34">Effects of genotype at the loci <italic>Cypr4</italic> and <italic>Cypr5</italic> on the concentration of IFN&#947; in supernatants of spleen cells of individual F<sub>2</sub> hybrids between OcB-9 and O20 stimulated by irradiated B10 splenocytes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Marker/locus</th><th align="left" colspan="3">Genotype</th><th align="left" rowspan="2"><italic>P</italic> value</th><th align="left" rowspan="2">Corrected <italic>P</italic></th></tr><tr><th align="left"><italic>oo</italic></th><th align="left"><italic>ob</italic></th><th align="left"><italic>bb</italic></th></tr></thead><tbody><tr><td align="left">D6Mit31 (<italic>Cypr4</italic>)</td><td align="left">7.74&#160;&#177;&#160;0.60 (<italic>n</italic>&#160;=&#160;64)</td><td align="left">5.77&#160;&#177;&#160;0.47 (<italic>n</italic>&#160;=&#160;105)</td><td align="left">3.78&#160;&#177;&#160;0.69 (<italic>n</italic>&#160;=&#160;63)</td><td char="." align="char">0.000100</td><td char="." align="char">0.00717</td></tr><tr><td align="left">D6Mit52 (<italic>Cypr5</italic>)</td><td align="left">3.66&#160;&#177;&#160;0.74 (<italic>n</italic>&#160;=&#160;55)</td><td align="left">5.09&#160;&#177;&#160;0.47 (<italic>n</italic>&#160;=&#160;121)</td><td align="left">9.43&#160;&#177;&#160;0.66 (<italic>n</italic>&#160;=&#160;63)</td><td char="." align="char">0.00000296</td><td char="." align="char">0.000257</td></tr></tbody></table><table-wrap-foot><p textid="35">The phenotypic values given for individual genotypes indicate mean and standard errors of the concentration of IFN&#947; and (in <italic>brackets</italic>) the number of mice (for computations the measured values of IFN&#947; in supernatants (ng/ml) were normalized by natural logarithm of (value&#160;+&#160;0.5) to the power of 0.005)</p></table-wrap-foot></table-wrap>
###xml 1690 1694 <span type="species:ncbi:10090">mice</span>
Statistical analysis revealed four genetic loci that influence level of IFNgamma in supernatants of (O20xOcB-9)F2 splenocytes stimulated by irradiated C57BL/10 cells. Two of these loci have individual effects, but the other two operate in mutual nonadditive interaction. Two loci, Cypr4 (Cytokine production 4) linked to D6Mit31 (corrected P value < 0.00717) and Cypr5 linked to D6Mit52 (corrected P value < 0.000257) have effect on IFNgamma production after alloantigen stimulation that is not influenced by interaction with other genes (main effects) (Table 1). These loci have an opposite effect on the studied trait. The homozygosity for the O20 allele of Cypr4 (oo) determines about twofold higher level of IFNgamma than the homozygosity of the B10.O20 allele (bb), whereas homozygosity for the O20 allele of Cypr5 is associated with about two-and-half fold decrease level of this cytokine than the homozygosity of the B10.O20 allele. Influence of the experimental group was evident (P < 1.75 x 10-24), but no significant interaction between experimental group and marker was observed.Table 1Effects of genotype at the loci Cypr4 and Cypr5 on the concentration of IFNgamma in supernatants of spleen cells of individual F2 hybrids between OcB-9 and O20 stimulated by irradiated B10 splenocytesMarker/locusGenotypeP valueCorrected PooobbbD6Mit31 (Cypr4)7.74 +/- 0.60 (n = 64)5.77 +/- 0.47 (n = 105)3.78 +/- 0.69 (n = 63)0.0001000.00717D6Mit52 (Cypr5)3.66 +/- 0.74 (n = 55)5.09 +/- 0.47 (n = 121)9.43 +/- 0.66 (n = 63)0.000002960.000257The phenotypic values given for individual genotypes indicate mean and standard errors of the concentration of IFNgamma and (in brackets) the number of mice (for computations the measured values of IFNgamma in supernatants (ng/ml) were normalized by natural logarithm of (value + 0.5) to the power of 0.005)
###end p 33
###begin p 34
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr4</italic>
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr5</italic>
###xml 128 129 124 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Effects of genotype at the loci Cypr4 and Cypr5 on the concentration of IFNgamma in supernatants of spleen cells of individual F2 hybrids between OcB-9 and O20 stimulated by irradiated B10 splenocytes
###end p 34
###begin p 35
###xml 128 136 124 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brackets</italic>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
The phenotypic values given for individual genotypes indicate mean and standard errors of the concentration of IFNgamma and (in brackets) the number of mice (for computations the measured values of IFNgamma in supernatants (ng/ml) were normalized by natural logarithm of (value + 0.5) to the power of 0.005)
###end p 35
###begin p 36
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr6</italic>
###xml 52 57 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr7</italic>
###xml 69 70 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 84 85 80 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 116 118 112 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bb</italic>
###xml 131 136 127 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr6</italic>
###xml 146 148 142 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">oo</italic>
###xml 161 166 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr7</italic>
###xml 203 208 199 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr7</italic>
###xml 243 248 239 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr6</italic>
###xml 395 400 387 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr6</italic>
###xml 405 410 397 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr7</italic>
###xml 442 443 434 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 749 750 733 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 842 847 822 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr4</italic>
###xml 952 953 932 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 976 981 956 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf4</italic>
###xml 989 991 969 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink">oo</italic>
###xml 1044 1046 1020 1022 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob</italic>
###xml 1080 1082 1052 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bb</italic>
###xml 1154 1163 1122 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr-Lynf</italic>
###xml 1247 1254 1215 1222 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 1286 1291 1254 1259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr6</italic>
###xml 1296 1301 1264 1269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr7</italic>
###xml 1371 1372 1335 1336 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1254 1443 1222 1407 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37">Effects of genotype at the loci <italic>Cypr6</italic> and <italic>Cypr7</italic> on the concentration of IFN&#947; in supernatants of spleen cells of F<sub>2</sub> hybrids between OcB-9 and O20 stimulated by irradiated B10 splenocytes</p>
###xml 1254 1443 1222 1407 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37">Effects of genotype at the loci <italic>Cypr6</italic> and <italic>Cypr7</italic> on the concentration of IFN&#947; in supernatants of spleen cells of F<sub>2</sub> hybrids between OcB-9 and O20 stimulated by irradiated B10 splenocytes</p></caption>
###xml 1443 1443 1407 1407 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"/>
###xml 1450 1457 1414 1421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(Cypr7)</italic>
###xml 1443 1457 1407 1421 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">D8Mit3 <italic>(Cypr7)</italic></th>
###xml 1443 1457 1407 1421 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2"/><th align="left" colspan="3">D8Mit3 <italic>(Cypr7)</italic></th></tr>
###xml 1457 1459 1421 1423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">oo</italic>
###xml 1457 1459 1421 1423 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>oo</italic></th>
###xml 1459 1461 1423 1425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob</italic>
###xml 1459 1461 1423 1425 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>ob</italic></th>
###xml 1461 1463 1425 1427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bb</italic>
###xml 1461 1463 1425 1427 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>bb</italic></th>
###xml 1457 1463 1421 1427 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"><italic>oo</italic></th><th align="left"><italic>ob</italic></th><th align="left"><italic>bb</italic></th></tr>
###xml 1443 1463 1407 1427 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="2"/><th align="left" colspan="3">D8Mit3 <italic>(Cypr7)</italic></th></tr><tr><th align="left"><italic>oo</italic></th><th align="left"><italic>ob</italic></th><th align="left"><italic>bb</italic></th></tr></thead>
###xml 1472 1477 1436 1441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr6</italic>
###xml 1463 1478 1427 1442 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">D4Mit54 (<italic>Cypr6</italic>)</td>
###xml 1463 1478 1427 1442 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">D4Mit54 (<italic>Cypr6</italic>)</td></tr>
###xml 1479 1481 1443 1445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">oo</italic>
###xml 1478 1481 1442 1445 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;<italic>oo</italic></td>
###xml 1496 1497 1458 1459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1481 1503 1445 1465 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">5.57&#160;&#177;&#160;1.89 (<italic>n</italic>&#160;=&#160;15)</td>
###xml 1518 1519 1478 1479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1503 1525 1465 1485 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">3.13&#160;&#177;&#160;0.93 (<italic>n</italic>&#160;=&#160;29)</td>
###xml 1541 1542 1499 1500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1525 1548 1485 1506 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">10.64&#160;&#177;&#160;1.57 (<italic>n</italic>&#160;=&#160;10)</td>
###xml 1478 1548 1442 1506 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;<italic>oo</italic></td><td char="&#177;" align="char">5.57&#160;&#177;&#160;1.89 (<italic>n</italic>&#160;=&#160;15)</td><td char="&#177;" align="char">3.13&#160;&#177;&#160;0.93 (<italic>n</italic>&#160;=&#160;29)</td><td char="&#177;" align="char">10.64&#160;&#177;&#160;1.57 (<italic>n</italic>&#160;=&#160;10)</td></tr>
###xml 1549 1551 1507 1509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob</italic>
###xml 1548 1551 1506 1509 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;<italic>ob</italic></td>
###xml 1566 1567 1522 1523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1551 1573 1509 1529 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">5.16&#160;&#177;&#160;0.83 (<italic>n</italic>&#160;=&#160;31)</td>
###xml 1588 1589 1542 1543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1573 1595 1529 1549 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">5.66&#160;&#177;&#160;0.55 (<italic>n</italic>&#160;=&#160;58)</td>
###xml 1610 1611 1562 1563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1595 1617 1549 1569 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">4.67&#160;&#177;&#160;0.69 (<italic>n</italic>&#160;=&#160;33)</td>
###xml 1548 1617 1506 1569 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;<italic>ob</italic></td><td char="&#177;" align="char">5.16&#160;&#177;&#160;0.83 (<italic>n</italic>&#160;=&#160;31)</td><td char="&#177;" align="char">5.66&#160;&#177;&#160;0.55 (<italic>n</italic>&#160;=&#160;58)</td><td char="&#177;" align="char">4.67&#160;&#177;&#160;0.69 (<italic>n</italic>&#160;=&#160;33)</td></tr>
###xml 1618 1620 1570 1572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bb</italic>
###xml 1617 1620 1569 1572 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;<italic>bb</italic></td>
###xml 1635 1636 1585 1586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1620 1642 1572 1592 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">9.06&#160;&#177;&#160;1.38 (<italic>n</italic>&#160;=&#160;10)</td>
###xml 1657 1658 1605 1606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1642 1664 1592 1612 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">4.77&#160;&#177;&#160;0.77 (<italic>n</italic>&#160;=&#160;28)</td>
###xml 1679 1680 1625 1626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1664 1686 1612 1632 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">4.61&#160;&#177;&#160;0.85 (<italic>n</italic>&#160;=&#160;11)</td>
###xml 1617 1686 1569 1632 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;<italic>bb</italic></td><td char="&#177;" align="char">9.06&#160;&#177;&#160;1.38 (<italic>n</italic>&#160;=&#160;10)</td><td char="&#177;" align="char">4.77&#160;&#177;&#160;0.77 (<italic>n</italic>&#160;=&#160;28)</td><td char="&#177;" align="char">4.61&#160;&#177;&#160;0.85 (<italic>n</italic>&#160;=&#160;11)</td></tr>
###xml 1463 1686 1427 1632 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" colspan="4">D4Mit54 (<italic>Cypr6</italic>)</td></tr><tr><td align="left">&#160;<italic>oo</italic></td><td char="&#177;" align="char">5.57&#160;&#177;&#160;1.89 (<italic>n</italic>&#160;=&#160;15)</td><td char="&#177;" align="char">3.13&#160;&#177;&#160;0.93 (<italic>n</italic>&#160;=&#160;29)</td><td char="&#177;" align="char">10.64&#160;&#177;&#160;1.57 (<italic>n</italic>&#160;=&#160;10)</td></tr><tr><td align="left">&#160;<italic>ob</italic></td><td char="&#177;" align="char">5.16&#160;&#177;&#160;0.83 (<italic>n</italic>&#160;=&#160;31)</td><td char="&#177;" align="char">5.66&#160;&#177;&#160;0.55 (<italic>n</italic>&#160;=&#160;58)</td><td char="&#177;" align="char">4.67&#160;&#177;&#160;0.69 (<italic>n</italic>&#160;=&#160;33)</td></tr><tr><td align="left">&#160;<italic>bb</italic></td><td char="&#177;" align="char">9.06&#160;&#177;&#160;1.38 (<italic>n</italic>&#160;=&#160;10)</td><td char="&#177;" align="char">4.77&#160;&#177;&#160;0.77 (<italic>n</italic>&#160;=&#160;28)</td><td char="&#177;" align="char">4.61&#160;&#177;&#160;0.85 (<italic>n</italic>&#160;=&#160;11)</td></tr></tbody>
###xml 1443 1686 1407 1632 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="3">D8Mit3 <italic>(Cypr7)</italic></th></tr><tr><th align="left"><italic>oo</italic></th><th align="left"><italic>ob</italic></th><th align="left"><italic>bb</italic></th></tr></thead><tbody><tr><td align="left" colspan="4">D4Mit54 (<italic>Cypr6</italic>)</td></tr><tr><td align="left">&#160;<italic>oo</italic></td><td char="&#177;" align="char">5.57&#160;&#177;&#160;1.89 (<italic>n</italic>&#160;=&#160;15)</td><td char="&#177;" align="char">3.13&#160;&#177;&#160;0.93 (<italic>n</italic>&#160;=&#160;29)</td><td char="&#177;" align="char">10.64&#160;&#177;&#160;1.57 (<italic>n</italic>&#160;=&#160;10)</td></tr><tr><td align="left">&#160;<italic>ob</italic></td><td char="&#177;" align="char">5.16&#160;&#177;&#160;0.83 (<italic>n</italic>&#160;=&#160;31)</td><td char="&#177;" align="char">5.66&#160;&#177;&#160;0.55 (<italic>n</italic>&#160;=&#160;58)</td><td char="&#177;" align="char">4.67&#160;&#177;&#160;0.69 (<italic>n</italic>&#160;=&#160;33)</td></tr><tr><td align="left">&#160;<italic>bb</italic></td><td char="&#177;" align="char">9.06&#160;&#177;&#160;1.38 (<italic>n</italic>&#160;=&#160;10)</td><td char="&#177;" align="char">4.77&#160;&#177;&#160;0.77 (<italic>n</italic>&#160;=&#160;28)</td><td char="&#177;" align="char">4.61&#160;&#177;&#160;0.85 (<italic>n</italic>&#160;=&#160;11)</td></tr></tbody></table>
###xml 1814 1822 1756 1764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brackets</italic>
###xml 1860 1861 1802 1803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1874 1875 1816 1817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">o</italic>
###xml 1878 1879 1820 1821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1896 1897 1838 1839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1915 1916 1857 1858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1919 1920 1861 1862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1686 1961 1632 1903 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="38">The phenotypic values given for individual genotypes indicate mean and standard errors of the concentration of IFN&#947; and (in <italic>brackets</italic>) the number of mice. (B10.O20 allele <italic>b</italic>, O20 allele <italic>o</italic>), <italic>P</italic> value&#160;=&#160;nominal <italic>P</italic> value, corrected <italic>P</italic>&#160;=&#160;<italic>P</italic> value corrected for total genome screen)</p>
###xml 1961 1962 1903 1904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1991 1992 1933 1934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1961 2008 1903 1950 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="39"><italic>P</italic> value&#160;=&#160;0.000189, corrected <italic>P</italic> value&#160;=&#160;0.00111</p>
###xml 1686 2008 1632 1950 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="38">The phenotypic values given for individual genotypes indicate mean and standard errors of the concentration of IFN&#947; and (in <italic>brackets</italic>) the number of mice. (B10.O20 allele <italic>b</italic>, O20 allele <italic>o</italic>), <italic>P</italic> value&#160;=&#160;nominal <italic>P</italic> value, corrected <italic>P</italic>&#160;=&#160;<italic>P</italic> value corrected for total genome screen)</p><p textid="39"><italic>P</italic> value&#160;=&#160;0.000189, corrected <italic>P</italic> value&#160;=&#160;0.00111</p></table-wrap-foot>
###xml 1247 2008 1215 1950 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="37">Effects of genotype at the loci <italic>Cypr6</italic> and <italic>Cypr7</italic> on the concentration of IFN&#947; in supernatants of spleen cells of F<sub>2</sub> hybrids between OcB-9 and O20 stimulated by irradiated B10 splenocytes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="3">D8Mit3 <italic>(Cypr7)</italic></th></tr><tr><th align="left"><italic>oo</italic></th><th align="left"><italic>ob</italic></th><th align="left"><italic>bb</italic></th></tr></thead><tbody><tr><td align="left" colspan="4">D4Mit54 (<italic>Cypr6</italic>)</td></tr><tr><td align="left">&#160;<italic>oo</italic></td><td char="&#177;" align="char">5.57&#160;&#177;&#160;1.89 (<italic>n</italic>&#160;=&#160;15)</td><td char="&#177;" align="char">3.13&#160;&#177;&#160;0.93 (<italic>n</italic>&#160;=&#160;29)</td><td char="&#177;" align="char">10.64&#160;&#177;&#160;1.57 (<italic>n</italic>&#160;=&#160;10)</td></tr><tr><td align="left">&#160;<italic>ob</italic></td><td char="&#177;" align="char">5.16&#160;&#177;&#160;0.83 (<italic>n</italic>&#160;=&#160;31)</td><td char="&#177;" align="char">5.66&#160;&#177;&#160;0.55 (<italic>n</italic>&#160;=&#160;58)</td><td char="&#177;" align="char">4.67&#160;&#177;&#160;0.69 (<italic>n</italic>&#160;=&#160;33)</td></tr><tr><td align="left">&#160;<italic>bb</italic></td><td char="&#177;" align="char">9.06&#160;&#177;&#160;1.38 (<italic>n</italic>&#160;=&#160;10)</td><td char="&#177;" align="char">4.77&#160;&#177;&#160;0.77 (<italic>n</italic>&#160;=&#160;28)</td><td char="&#177;" align="char">4.61&#160;&#177;&#160;0.85 (<italic>n</italic>&#160;=&#160;11)</td></tr></tbody></table><table-wrap-foot><p textid="38">The phenotypic values given for individual genotypes indicate mean and standard errors of the concentration of IFN&#947; and (in <italic>brackets</italic>) the number of mice. (B10.O20 allele <italic>b</italic>, O20 allele <italic>o</italic>), <italic>P</italic> value&#160;=&#160;nominal <italic>P</italic> value, corrected <italic>P</italic>&#160;=&#160;<italic>P</italic> value corrected for total genome screen)</p><p textid="39"><italic>P</italic> value&#160;=&#160;0.000189, corrected <italic>P</italic> value&#160;=&#160;0.00111</p></table-wrap-foot></table-wrap>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 678 682 <span type="species:ncbi:10090">mice</span>
###xml 1838 1842 <span type="species:ncbi:10090">mice</span>
Cypr6 influences IFNgamma level in interaction with Cypr7 (corrected P < 0.00111). F2 mice with homozygous B10.O20 (bb) alleles at Cypr6 and O20 (oo) alleles at Cypr7 or homozygous for B10.O20 allele at Cypr7 and homozygous for O20 alleles in Cypr6 produce approximately twice higher IFNgamma level in supernatants in alloantigen-stimulated spleen cells in comparison with other combinations of Cypr6 and Cypr7 O20 and B10.O20 alleles (Table 2). The levels of IFNgamma seem to be negatively correlated with the intensity of lymphocyte infiltration, both in the strains and in comparable genotypes. The production of IFNgamma is higher in the strain OcB-9 than O20, while in O20 mice the numbers of intratumoral lymphocytes are higher than in OcB-9 [8]. A similar negative correlation is seen also at locus level: IFNgamma levels at the three Cypr4 genotypes are negatively correlated with lymphocyte infiltration scores at the corresponding genotypes [9] of the co-localizing Lynf4 locus: oo: IFNgamma-7.74 ng/ml, infiltration score (IS)-0.04; ob: IFNgamma-5.77 ng/ml, (IS)-0.39; bb: IFNgamma-3.78 ng/ml, (IS)-0.34. Allelic correlations within the other Cypr-Lynf could not be assessed, because these loci were defined by inter-locus interactions.Table 2Effects of genotype at the loci Cypr6 and Cypr7 on the concentration of IFNgamma in supernatants of spleen cells of F2 hybrids between OcB-9 and O20 stimulated by irradiated B10 splenocytesD8Mit3 (Cypr7)ooobbbD4Mit54 (Cypr6) oo5.57 +/- 1.89 (n = 15)3.13 +/- 0.93 (n = 29)10.64 +/- 1.57 (n = 10) ob5.16 +/- 0.83 (n = 31)5.66 +/- 0.55 (n = 58)4.67 +/- 0.69 (n = 33) bb9.06 +/- 1.38 (n = 10)4.77 +/- 0.77 (n = 28)4.61 +/- 0.85 (n = 11)The phenotypic values given for individual genotypes indicate mean and standard errors of the concentration of IFNgamma and (in brackets) the number of mice. (B10.O20 allele b, O20 allele o), P value = nominal P value, corrected P = P value corrected for total genome screen)P value = 0.000189, corrected P value = 0.00111
###end p 36
###begin p 37
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr6</italic>
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr7</italic>
###xml 117 118 113 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Effects of genotype at the loci Cypr6 and Cypr7 on the concentration of IFNgamma in supernatants of spleen cells of F2 hybrids between OcB-9 and O20 stimulated by irradiated B10 splenocytes
###end p 37
###begin p 38
###xml 128 136 124 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brackets</italic>
###xml 174 175 170 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 188 189 184 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">o</italic>
###xml 192 193 188 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 210 211 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 229 230 225 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 233 234 229 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
The phenotypic values given for individual genotypes indicate mean and standard errors of the concentration of IFNgamma and (in brackets) the number of mice. (B10.O20 allele b, O20 allele o), P value = nominal P value, corrected P = P value corrected for total genome screen)
###end p 38
###begin p 39
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 30 31 30 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P value = 0.000189, corrected P value = 0.00111
###end p 39
###begin title 40
Discussion
###end title 40
###begin p 41
###xml 290 292 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 294 296 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 320 322 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 335 337 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 355 357 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 359 361 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 792 794 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 813 815 809 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 1437 1439 1429 1431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1441 1443 1433 1435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 1616 1618 1608 1610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 1620 1622 1612 1614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 1692 1713 1684 1705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">Materials and methods</xref>
###xml 1868 1870 1860 1862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 1959 1961 1951 1953 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 1961 1963 1953 1955 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pz</italic>
###xml 1961 1963 1953 1955 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>pz</italic></sup>
###xml 2015 2017 2007 2009 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 2017 2018 2009 2010 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 2017 2018 2009 2010 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></sup>
###xml 2295 2300 2283 2288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mtv13</italic>
###xml 2302 2306 2290 2294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mls1</italic>
###xml 2309 2311 2297 2299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 2383 2387 2371 2375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr</italic>
In the present study, we demonstrate genetic linkage between in vitro production of IFNgamma and in vivo lymphocyte infiltration of tumors. Previously, we have shown that responder's genotype strongly influences various in vitro responses of lymphocytes to stimulation by allogeneic cells [16, 17], anti-CD3 antibodies [28], mitogens [32], and cytokines [11, 28]. Importantly, in MLC these differences in response were obvious in spite of identical MHC incompatibility. We have shown that these differences are controlled by several loci with quantitative additive effects, and that different components of a response, for example proliferation or production of different cytokines, are controlled by different genes. We observed that two genetic loci that control activation of macrophages [10] and lymphocytes [11] co-localize with the genes that control susceptibility to lung tumors. This suggested that the loci regulating activity of lymphocytes and macrophages in vitro could have also in vivo effect on tumor growth. The genetic analysis of production of IFNgamma by responder lymphocytes in allogeneic mixed lymphocyte cultures demonstrated four genetic loci with significant influence. We analyzed the difference in the phenotype of interferon production between the strain O20 and the RC strain OcB-9 that is in about 87.5% genes identical to O20, but received a random subset of about 12.5% of genes from the strain B10.O20 [18, 27]. The genetic material obtained from B10.O20 is almost entirely contained in several contiguous chromosomal segments, mostly 10-20 cM long. They were described previously [27, 33] and are covered by 15 polymorphic microsatellite markers listed in "Materials and methods" section. Thus, any genetic differences between these two strains must be controlled by a gene or genes located in one of these B10.O20-derived segments [34]. It should be pointed out that the strains O20 and OcB-9 have identical MHC haplotype (H2pz), so they respond to the same MHC incompatibility (H2b) and any difference in the response must be host-related. The stimulation by non-MHC alloantigens is not a likely cause of the observed differences in production of IFNgamma between O20 and OcB-9, because the two strains have the same genotype at the strong stimulatory locus Mtv13 (Mls1) [27] and no other stimulators in MLC were described in the vicinity of the Cypr loci mapped here.
###end p 41
###begin p 42
###xml 185 186 181 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 318 323 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Alan2</italic>
###xml 325 327 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 432 437 424 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr6</italic>
###xml 529 534 521 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr4</italic>
###xml 536 537 528 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">5</italic>
###xml 543 544 535 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">7</italic>
###xml 803 805 791 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
However, the higher production of IFNgamma by OcB-9 cells is not likely a mere consequence of a higher proliferative response. We measured proliferation in parallel MLCs of individual F2 hybrid animals that were tested for IFNgamma production. We found in that population only one locus controlling the proliferation, Alan2 [17]. It is linked to a marker that is different from but relatively close (6 cM) to the marker identifying Cypr6, so the identity of the two loci is neither indicated nor ruled out. The other three loci (Cypr4, 5, and 7) were not linked to proliferative activity in MLR. This prevailing genetic independence of proliferation and IFNgamma production in MLC is similar to the extensively documented distinct genetic control of lymphocyte proliferation and IL-2 production in MLC [19].
###end p 42
###begin p 43
###xml 98 102 98 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr</italic>
###xml 180 184 176 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf</italic>
###xml 244 249 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr4</italic>
###xml 250 255 246 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf4</italic>
###xml 257 262 253 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr5</italic>
###xml 263 268 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf3</italic>
###xml 270 275 266 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr6</italic>
###xml 276 281 272 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf1</italic>
###xml 283 288 279 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr7</italic>
###xml 289 294 285 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf2</italic>
###xml 309 318 305 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr-Lynf</italic>
###xml 396 400 392 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf</italic>
###xml 585 586 581 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
An unexpected feature of our data is the complete co-localization of the four newly detected loci Cypr controlling production of IFNgamma in mixed lymphocyte culture with the four Lynf loci that control infiltration of lymphocytes into tumors: Cypr4-Lynf4; Cypr5-Lynf3; Cypr6-Lynf1; Cypr7-Lynf2. This general Cypr-Lynf co-localization contrasts sharply with a complete lack of co-localization of Lynf loci with any genes encoding the more than 60 molecules that were either reported to participate in traffic of lymphocytes from the circulation to tumors or belong to the same family [9]. This suggests that, contrary to the prevailing emphasis in the literature, the principal control of capacity of lymphocytes to infiltrate tumors might reside in the regulation of the processes of lymphocyte activation.
###end p 43
###begin p 44
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr</italic>
###xml 240 241 240 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 244 249 244 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr4</italic>
###xml 279 284 279 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mmom1</italic>
###xml 286 290 286 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ots1</italic>
###xml 292 297 292 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pas1c</italic>
###xml 299 305 299 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Skts11</italic>
###xml 307 312 307 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr5</italic>
###xml 327 332 327 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ltsd8</italic>
###xml 334 339 334 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr6</italic>
###xml 376 442 376 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gct1, Ltsd4, Naad5, Nbl1, Pcts, Sluc6, Sluc21, Ssic1, Stmn1, Tlsr3</italic>
###xml 448 453 448 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr7</italic>
###xml 464 510 464 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlc1, Ltq, Ltsd3, Mfhas1, Sluc20, Scc8, Poats1</italic>
###xml 511 518 511 518 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 546 550 546 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr</italic>
###xml 518 593 518 593 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="45">Co-localization of the four <italic>Cypr</italic> loci with cancer susceptibility loci/genes</p>
###xml 518 593 518 593 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="45">Co-localization of the four <italic>Cypr</italic> loci with cancer susceptibility loci/genes</p></caption>
###xml 593 618 593 618 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Locus with border markers</th>
###xml 618 624 618 624 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Marker</th>
###xml 624 626 624 626 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">cM</th>
###xml 626 636 626 636 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Locus/Gene</th>
###xml 636 638 636 638 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">cM</th>
###xml 638 647 638 647 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Reference</th>
###xml 593 647 593 647 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Locus with border markers</th><th align="left">Marker</th><th align="left">cM</th><th align="left">Locus/Gene</th><th align="left">cM</th><th align="left">Reference</th></tr>
###xml 593 647 593 647 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Locus with border markers</th><th align="left">Marker</th><th align="left">cM</th><th align="left">Locus/Gene</th><th align="left">cM</th><th align="left">Reference</th></tr></thead>
###xml 652 653 652 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">o</italic>
###xml 647 654 647 654 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">O20 (<italic>o</italic>)</td>
###xml 654 661 654 661 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">D6Mit29</td>
###xml 661 666 661 666 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">36.50</td>
###xml 666 671 666 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf4</italic>
###xml 666 699 666 699 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Lynf4</italic> (Lymphocyte infiltration 4)</td>
###xml 699 704 699 704 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">35.15</td>
###xml 705 706 705 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 704 707 704 707 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td>
###xml 647 707 647 707 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit29</td><td align="left">36.50</td><td align="left"><italic>Lynf4</italic> (Lymphocyte infiltration 4)</td><td char="." align="char">35.15</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr>
###xml 712 713 712 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 707 714 707 714 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">B10 (<italic>b</italic>)</td>
###xml 714 721 714 721 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">D6Mit31</td>
###xml 721 726 721 726 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">38.50</td>
###xml 726 732 726 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Skts11</italic>
###xml 726 763 726 763 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Skts11</italic> (skin tumor susceptibility 11)</td>
###xml 763 768 763 768 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">36.50</td>
###xml 769 771 769 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
###xml 768 772 768 772 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR42">42</xref>]</td>
###xml 707 772 707 772 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit31</td><td align="left">38.50</td><td align="left"><italic>Skts11</italic> (skin tumor susceptibility 11)</td><td char="." align="char">36.50</td><td align="left">[<xref ref-type="bibr" rid="CR42">42</xref>]</td></tr>
###xml 772 777 772 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr4</italic>
###xml 772 777 772 777 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Cypr4</italic></bold>
###xml 777 778 777 778 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(</bold>
###xml 778 779 778 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 778 779 778 779 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></bold>
###xml 779 780 779 780 <bold xmlns:xlink="http://www.w3.org/1999/xlink">)</bold>
###xml 772 780 772 780 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><bold><italic>Cypr4</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td>
###xml 780 787 780 787 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">D6Mit31</td>
###xml 787 792 787 792 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">38.50</td>
###xml 792 797 792 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pas1c</italic>
###xml 792 835 792 835 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Pas1c</italic> (pulmonary adenoma susceptibility 1c)</td>
###xml 835 840 835 840 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">37.00</td>
###xml 841 843 841 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
###xml 840 844 840 844 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR43">43</xref>]</td>
###xml 772 844 772 844 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><bold><italic>Cypr4</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left">D6Mit31</td><td align="left">38.50</td><td align="left"><italic>Pas1c</italic> (pulmonary adenoma susceptibility 1c)</td><td char="." align="char">37.00</td><td align="left">[<xref ref-type="bibr" rid="CR43">43</xref>]</td></tr>
###xml 849 850 849 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 844 851 844 851 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">B10 (<italic>b</italic>)</td>
###xml 851 859 851 859 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">D6Mit327</td>
###xml 859 864 859 864 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">46.50</td>
###xml 864 869 864 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mmom3</italic>
###xml 891 895 891 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Min3</italic>
###xml 864 896 864 896 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Mmom3</italic> (mammary modifier of <italic>Min3</italic>)</td>
###xml 896 901 896 901 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">38.50</td>
###xml 902 904 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">44</xref>
###xml 901 905 901 905 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR44">44</xref>]</td>
###xml 844 905 844 905 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit327</td><td align="left">46.50</td><td align="left"><italic>Mmom3</italic> (mammary modifier of <italic>Min3</italic>)</td><td char="." align="char">38.50</td><td align="left">[<xref ref-type="bibr" rid="CR44">44</xref>]</td></tr>
###xml 910 911 910 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink">o</italic>
###xml 905 912 905 912 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">O20 (<italic>o</italic>)</td>
###xml 912 919 912 919 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">D6Mit10</td>
###xml 919 924 919 924 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">48.70</td>
###xml 924 928 924 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ots1</italic>
###xml 924 964 924 964 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Ots1</italic> (ovarian teratoma susceptibility 1)</td>
###xml 964 969 964 969 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">40.00</td>
###xml 970 972 970 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">45</xref>
###xml 969 973 969 973 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR45">45</xref>]</td>
###xml 905 973 905 973 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit10</td><td align="left">48.70</td><td align="left"><italic>Ots1</italic> (ovarian teratoma susceptibility 1)</td><td char="." align="char">40.00</td><td align="left">[<xref ref-type="bibr" rid="CR45">45</xref>]</td></tr>
###xml 978 979 978 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink">o</italic>
###xml 973 980 973 980 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">O20 (<italic>o</italic>)</td>
###xml 980 988 980 988 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">D6Mit334</td>
###xml 988 993 988 993 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">60.75</td>
###xml 993 998 993 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ltsd8</italic>
###xml 993 1031 993 1031 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Ltsd8</italic> (lung tumor shape-determining 8)</td>
###xml 1031 1036 1031 1036 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">61.20</td>
###xml 1037 1039 1037 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">46</xref>
###xml 1036 1040 1036 1040 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td>
###xml 973 1040 973 1040 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit334</td><td align="left">60.75</td><td align="left"><italic>Ltsd8</italic> (lung tumor shape-determining 8)</td><td char="." align="char">61.20</td><td align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr>
###xml 1045 1046 1045 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1040 1047 1040 1047 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">B10 (<italic>b</italic>)</td>
###xml 1047 1055 1047 1055 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">D6Mit256</td>
###xml 1055 1060 1055 1060 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">60.95</td>
###xml 1060 1065 1060 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf3</italic>
###xml 1060 1093 1060 1093 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Lynf3</italic> (Lymphocyte infiltration 3)</td>
###xml 1093 1098 1093 1098 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">61.20</td>
###xml 1099 1100 1099 1100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 1098 1101 1098 1101 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td>
###xml 1040 1101 1040 1101 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit256</td><td align="left">60.95</td><td align="left"><italic>Lynf3</italic> (Lymphocyte infiltration 3)</td><td char="." align="char">61.20</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr>
###xml 1101 1106 1101 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr5</italic>
###xml 1101 1106 1101 1106 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Cypr5</italic></bold>
###xml 1106 1107 1106 1107 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(</bold>
###xml 1107 1108 1107 1108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1107 1108 1107 1108 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></bold>
###xml 1108 1109 1108 1109 <bold xmlns:xlink="http://www.w3.org/1999/xlink">)</bold>
###xml 1101 1109 1101 1109 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><bold><italic>Cypr5</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td>
###xml 1109 1116 1109 1116 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">D6Mit52</td>
###xml 1116 1121 1116 1121 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">61.40</td>
###xml 1121 1121 1121 1121 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1121 1121 1121 1121 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1121 1121 1121 1121 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1101 1121 1101 1121 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><bold><italic>Cypr5</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left">D6Mit52</td><td align="left">61.40</td><td align="left"/><td char="." align="char"/><td align="left"/></tr>
###xml 1126 1127 1126 1127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1121 1128 1121 1128 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">B10 (<italic>b</italic>)</td>
###xml 1128 1136 1128 1136 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">D6Mit370</td>
###xml 1136 1141 1136 1141 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">62.67</td>
###xml 1141 1141 1141 1141 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1141 1141 1141 1141 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1141 1141 1141 1141 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1121 1141 1121 1141 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit370</td><td align="left">62.67</td><td align="left"/><td char="." align="char"/><td align="left"/></tr>
###xml 1146 1147 1146 1147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">o</italic>
###xml 1141 1148 1141 1148 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">O20 (<italic>o</italic>)</td>
###xml 1148 1155 1148 1155 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">D6Mit13</td>
###xml 1155 1160 1155 1160 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">63.60</td>
###xml 1160 1160 1160 1160 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1160 1160 1160 1160 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1160 1160 1160 1160 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1141 1160 1141 1160 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit13</td><td align="left">63.60</td><td align="left"/><td char="." align="char"/><td align="left"/></tr>
###xml 1165 1166 1165 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">o</italic>
###xml 1160 1167 1160 1167 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">O20 (<italic>o</italic>)</td>
###xml 1167 1174 1167 1174 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">D4Mit37</td>
###xml 1174 1179 1174 1179 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">56.50</td>
###xml 1179 1182 1179 1182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lci</italic>
###xml 1179 1211 1179 1211 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Lci</italic> (liver cell immortalization)</td>
###xml 1211 1216 1211 1216 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">57.50</td>
###xml 1217 1219 1217 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">47</xref>
###xml 1216 1220 1216 1220 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR47">47</xref>]</td>
###xml 1160 1220 1160 1220 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">O20 (<italic>o</italic>)</td><td align="left">D4Mit37</td><td align="left">56.50</td><td align="left"><italic>Lci</italic> (liver cell immortalization)</td><td char="." align="char">57.50</td><td align="left">[<xref ref-type="bibr" rid="CR47">47</xref>]</td></tr>
###xml 1225 1226 1225 1226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1220 1227 1220 1227 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">B10 (<italic>b</italic>)</td>
###xml 1227 1234 1227 1234 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">D4Mit11</td>
###xml 1234 1239 1234 1239 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">57.40</td>
###xml 1239 1244 1239 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Naad4</italic>
###xml 1239 1280 1239 1280 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Naad4</italic> (Neu associated allelic deletion 4)</td>
###xml 1280 1285 1280 1285 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">57.40</td>
###xml 1286 1288 1286 1288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">48</xref>
###xml 1285 1289 1285 1289 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR48">48</xref>]</td>
###xml 1220 1289 1220 1289 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">B10 (<italic>b</italic>)</td><td align="left">D4Mit11</td><td align="left">57.40</td><td align="left"><italic>Naad4</italic> (Neu associated allelic deletion 4)</td><td char="." align="char">57.40</td><td align="left">[<xref ref-type="bibr" rid="CR48">48</xref>]</td></tr>
###xml 1289 1294 1289 1294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr6</italic>
###xml 1289 1294 1289 1294 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Cypr6</italic></bold>
###xml 1294 1295 1294 1295 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(</bold>
###xml 1295 1296 1295 1296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1295 1296 1295 1296 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></bold>
###xml 1296 1297 1296 1297 <bold xmlns:xlink="http://www.w3.org/1999/xlink">)</bold>
###xml 1289 1297 1289 1297 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="12"><bold><italic>Cypr6</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td>
###xml 1297 1304 1297 1304 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="12">D4Mit54</td>
###xml 1304 1309 1304 1309 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="12">66.00</td>
###xml 1309 1313 1309 1313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ril3</italic>
###xml 1309 1356 1309 1356 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Ril3</italic> (radiation-induced leukemia sensitivity 3)</td>
###xml 1356 1361 1356 1361 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">60.00</td>
###xml 1362 1364 1362 1364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">49</xref>
###xml 1361 1365 1361 1365 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR49">49</xref>]</td>
###xml 1289 1365 1289 1365 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="12"><bold><italic>Cypr6</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left" rowspan="12">D4Mit54</td><td align="left" rowspan="12">66.00</td><td align="left"><italic>Ril3</italic> (radiation-induced leukemia sensitivity 3)</td><td char="." align="char">60.00</td><td align="left">[<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr>
###xml 1365 1371 1365 1371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sluc21</italic>
###xml 1365 1406 1365 1406 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Sluc21</italic> (susceptibility to lung cancer 21)</td>
###xml 1406 1411 1406 1411 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">63.00</td>
###xml 1412 1414 1412 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 1411 1415 1411 1415 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR30">30</xref>]</td>
###xml 1365 1415 1365 1415 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>Sluc21</italic> (susceptibility to lung cancer 21)</td><td char="." align="char">63.00</td><td align="left">[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr>
###xml 1415 1420 1415 1420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tlsr3</italic>
###xml 1415 1458 1415 1458 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Tlsr3</italic> (thymic lymphoma suppressor region 3)</td>
###xml 1458 1463 1458 1463 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">63.10</td>
###xml 1464 1466 1464 1466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">50</xref>
###xml 1463 1467 1463 1467 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR50">50</xref>]</td>
###xml 1415 1467 1415 1467 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>Tlsr3</italic> (thymic lymphoma suppressor region 3)</td><td char="." align="char">63.10</td><td align="left">[<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr>
###xml 1467 1472 1467 1472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Stmn1</italic>
###xml 1467 1485 1467 1485 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Stmn1</italic> (stathmin 1)</td>
###xml 1485 1490 1485 1490 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">65.70</td>
###xml 1491 1493 1491 1493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">51</xref>
###xml 1490 1494 1490 1494 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR51">51</xref>]</td>
###xml 1467 1494 1467 1494 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>Stmn1</italic> (stathmin 1)</td><td char="." align="char">65.70</td><td align="left">[<xref ref-type="bibr" rid="CR51">51</xref>]</td></tr>
###xml 1494 1499 1494 1499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Naad5</italic>
###xml 1494 1535 1494 1535 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Naad5</italic> (Neu associated allelic deletion 5)</td>
###xml 1535 1540 1535 1540 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">66.00</td>
###xml 1541 1543 1541 1543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR52">52</xref>
###xml 1540 1544 1540 1544 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR52">52</xref>]</td>
###xml 1494 1544 1494 1544 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>Naad5</italic> (Neu associated allelic deletion 5)</td><td char="." align="char">66.00</td><td align="left">[<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr>
###xml 1544 1549 1544 1549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ltsd4</italic>
###xml 1544 1582 1544 1582 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Ltsd4</italic> (lung tumor shape-determining 4)</td>
###xml 1582 1587 1582 1587 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">67.00</td>
###xml 1588 1590 1588 1590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">46</xref>
###xml 1587 1591 1587 1591 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td>
###xml 1544 1591 1544 1591 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>Ltsd4</italic> (lung tumor shape-determining 4)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr>
###xml 1591 1596 1591 1596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sluc6</italic>
###xml 1591 1630 1591 1630 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Sluc6</italic> (susceptibility to lung cancer 6)</td>
###xml 1630 1635 1630 1635 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">67.00</td>
###xml 1636 1638 1636 1638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR53">53</xref>
###xml 1635 1639 1635 1639 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR53">53</xref>]</td>
###xml 1591 1639 1591 1639 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>Sluc6</italic> (susceptibility to lung cancer 6)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR53">53</xref>]</td></tr>
###xml 1639 1644 1639 1644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf1</italic>
###xml 1639 1672 1639 1672 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Lynf1</italic> (Lymphocyte infiltration 1)</td>
###xml 1672 1677 1672 1677 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">67.00</td>
###xml 1678 1679 1678 1679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 1677 1680 1677 1680 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td>
###xml 1639 1680 1639 1680 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>Lynf1</italic> (Lymphocyte infiltration 1)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr>
###xml 1680 1685 1680 1685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ssic1</italic>
###xml 1680 1731 1680 1731 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Ssic1</italic> (susceptibility to small intestinal cancer 1)</td>
###xml 1731 1736 1731 1736 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">67.00</td>
###xml 1737 1739 1737 1739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">54</xref>
###xml 1736 1740 1736 1740 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR54">54</xref>]</td>
###xml 1680 1740 1680 1740 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>Ssic1</italic> (susceptibility to small intestinal cancer 1)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR54">54</xref>]</td></tr>
###xml 1740 1744 1740 1744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nbl1</italic>
###xml 1740 1793 1740 1793 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Nbl1</italic> (neuroblastoma, suppression of tumorigenicity 1)</td>
###xml 1793 1798 1793 1798 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">70.00</td>
###xml 1799 1801 1799 1801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR55">55</xref>
###xml 1798 1802 1798 1802 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR55">55</xref>]</td>
###xml 1740 1802 1740 1802 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>Nbl1</italic> (neuroblastoma, suppression of tumorigenicity 1)</td><td char="." align="char">70.00</td><td align="left">[<xref ref-type="bibr" rid="CR55">55</xref>]</td></tr>
###xml 1802 1806 1802 1806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pcts</italic>
###xml 1802 1836 1802 1836 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Pcts</italic> (plasmacytoma susceptibility)</td>
###xml 1836 1841 1836 1841 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">70.00</td>
###xml 1842 1844 1842 1844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">56</xref>
###xml 1841 1845 1841 1845 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR56">56</xref>]</td>
###xml 1802 1845 1802 1845 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>Pcts</italic> (plasmacytoma susceptibility)</td><td char="." align="char">70.00</td><td align="left">[<xref ref-type="bibr" rid="CR56">56</xref>]</td></tr>
###xml 1845 1849 1845 1849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gct1</italic>
###xml 1845 1882 1845 1882 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Gct1</italic> (granulosa cell tumorigenesis 1)</td>
###xml 1882 1887 1882 1887 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">71.00</td>
###xml 1888 1890 1888 1890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR57">57</xref>
###xml 1887 1891 1887 1891 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR57">57</xref>]</td>
###xml 1845 1891 1845 1891 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>Gct1</italic> (granulosa cell tumorigenesis 1)</td><td char="." align="char">71.00</td><td align="left">[<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr>
###xml 1896 1897 1896 1897 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1891 1898 1891 1898 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">B10 (<italic>b</italic>)</td>
###xml 1898 1906 1898 1906 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">D4Mit342</td>
###xml 1906 1911 1906 1911 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">77.50</td>
###xml 1911 1916 1911 1916 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pctr2</italic>
###xml 1911 1944 1911 1944 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Pctr2</italic> (plasmacytoma resistance 2)</td>
###xml 1944 1949 1944 1949 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">73.50</td>
###xml 1950 1952 1950 1952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR58">58</xref>
###xml 1949 1953 1949 1953 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR58">58</xref>]</td>
###xml 1891 1953 1891 1953 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">B10 (<italic>b</italic>)</td><td align="left">D4Mit342</td><td align="left">77.50</td><td align="left"><italic>Pctr2</italic> (plasmacytoma resistance 2)</td><td char="." align="char">73.50</td><td align="left">[<xref ref-type="bibr" rid="CR58">58</xref>]</td></tr>
###xml 1958 1959 1958 1959 <italic xmlns:xlink="http://www.w3.org/1999/xlink">o</italic>
###xml 1953 1960 1953 1960 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">O20 (<italic>o</italic>)</td>
###xml 1960 1967 1960 1967 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">D4Mit59</td>
###xml 1967 1972 1967 1972 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">78.90</td>
###xml 1972 1977 1972 1977 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tlsr2</italic>
###xml 1972 2015 1972 2015 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Tlsr2</italic> (thymic lymphoma suppressor region 2)</td>
###xml 2015 2020 2015 2020 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">76.60</td>
###xml 2021 2023 2021 2023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">50</xref>
###xml 2020 2024 2020 2024 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR50">50</xref>]</td>
###xml 1953 2024 1953 2024 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">O20 (<italic>o</italic>)</td><td align="left">D4Mit59</td><td align="left">78.90</td><td align="left"><italic>Tlsr2</italic> (thymic lymphoma suppressor region 2)</td><td char="." align="char">76.60</td><td align="left">[<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr>
###xml 2029 2030 2029 2030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">o</italic>
###xml 2024 2031 2024 2031 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">O20 (<italic>o</italic>)</td>
###xml 2031 2052 2031 2052 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">Markers start at 1&#160;cM</td>
###xml 2052 2052 2052 2052 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3"/>
###xml 2052 2056 2052 2056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scc8</italic>
###xml 2052 2087 2052 2087 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Scc8</italic> (colon tumor susceptibility 8)</td>
###xml 2087 2090 2087 2090 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.0</td>
###xml 2091 2093 2091 2093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR59">59</xref>
###xml 2090 2094 2090 2094 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR59">59</xref>]</td>
###xml 2024 2094 2024 2094 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="3">O20 (<italic>o</italic>)</td><td align="left" rowspan="3">Markers start at 1&#160;cM</td><td align="left" rowspan="3"/><td align="left"><italic>Scc8</italic> (colon tumor susceptibility 8)</td><td char="." align="char">4.0</td><td align="left">[<xref ref-type="bibr" rid="CR59">59</xref>]</td></tr>
###xml 2094 2100 2094 2100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Poats1</italic>
###xml 2094 2149 2094 2149 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Poats1</italic> (post-ovarectomy adrenal tumor susceptibility 1)</td>
###xml 2149 2152 2149 2152 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">8.0</td>
###xml 2153 2155 2153 2155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR60">60</xref>
###xml 2152 2156 2152 2156 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR60">60</xref>]</td>
###xml 2094 2156 2094 2156 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>Poats1</italic> (post-ovarectomy adrenal tumor susceptibility 1)</td><td char="." align="char">8.0</td><td align="left">[<xref ref-type="bibr" rid="CR60">60</xref>]</td></tr>
###xml 2156 2161 2156 2161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ltsd3</italic>
###xml 2156 2194 2156 2194 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Ltsd3</italic> (lung tumor shape-determining 3)</td>
###xml 2194 2199 2194 2199 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10.00</td>
###xml 2200 2202 2200 2202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">46</xref>
###xml 2199 2203 2199 2203 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td>
###xml 2156 2203 2156 2203 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>Ltsd3</italic> (lung tumor shape-determining 3)</td><td char="." align="char">10.00</td><td align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr>
###xml 2208 2209 2208 2209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 2203 2210 2203 2210 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">B10 (<italic>b</italic>)</td>
###xml 2210 2218 2210 2218 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">D8Mit155</td>
###xml 2218 2222 2218 2222 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.00</td>
###xml 2222 2228 2222 2228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sluc20</italic>
###xml 2222 2263 2222 2263 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Sluc20</italic> (susceptibility to lung cancer 20)</td>
###xml 2263 2268 2263 2268 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10.00</td>
###xml 2269 2271 2269 2271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 2268 2272 2268 2272 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR30">30</xref>]</td>
###xml 2203 2272 2203 2272 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">B10 (<italic>b</italic>)</td><td align="left">D8Mit155</td><td align="left">1.00</td><td align="left"><italic>Sluc20</italic> (susceptibility to lung cancer 20)</td><td char="." align="char">10.00</td><td align="left">[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr>
###xml 2272 2277 2272 2277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr7</italic>
###xml 2272 2277 2272 2277 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Cypr7</italic></bold>
###xml 2277 2278 2277 2278 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(</bold>
###xml 2278 2279 2278 2279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 2278 2279 2278 2279 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></bold>
###xml 2279 2280 2279 2280 <bold xmlns:xlink="http://www.w3.org/1999/xlink">)</bold>
###xml 2272 2280 2272 2280 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"><bold><italic>Cypr7</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td>
###xml 2280 2286 2280 2286 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">D8Mit3</td>
###xml 2286 2291 2286 2291 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">10.00</td>
###xml 2291 2296 2291 2296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf2</italic>
###xml 2291 2324 2291 2324 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Lynf2</italic> (lymphocyte infiltration 2)</td>
###xml 2324 2329 2324 2329 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10.00</td>
###xml 2330 2331 2330 2331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 2329 2332 2329 2332 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td>
###xml 2272 2332 2272 2332 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="2"><bold><italic>Cypr7</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left" rowspan="2">D8Mit3</td><td align="left" rowspan="2">10.00</td><td align="left"><italic>Lynf2</italic> (lymphocyte infiltration 2)</td><td char="." align="char">10.00</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr>
###xml 2332 2338 2332 2338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mfhas1</italic>
###xml 2332 2392 2332 2392 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Mfhas1</italic> (malignant fibrous histiocytoma amplified sequence 1)</td>
###xml 2392 2397 2392 2397 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">20.00</td>
###xml 2398 2400 2398 2400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR61">61</xref>
###xml 2397 2401 2397 2401 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR61">61</xref>]</td>
###xml 2332 2401 2332 2401 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>Mfhas1</italic> (malignant fibrous histiocytoma amplified sequence 1)</td><td char="." align="char">20.00</td><td align="left">[<xref ref-type="bibr" rid="CR61">61</xref>]</td></tr>
###xml 2406 2407 2406 2407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 2401 2408 2401 2408 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">B10 (<italic>b</italic>)</td>
###xml 2408 2415 2408 2415 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">D8Mit98</td>
###xml 2415 2420 2415 2420 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">28.00</td>
###xml 2420 2424 2420 2424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlc1</italic>
###xml 2420 2452 2420 2452 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Dlc1</italic> (deleted in liver cancer 1)</td>
###xml 2452 2457 2452 2457 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">21.00</td>
###xml 2458 2460 2458 2460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR62">62</xref>
###xml 2457 2461 2457 2461 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR62">62</xref>]</td>
###xml 2401 2461 2401 2461 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">B10 (<italic>b</italic>)</td><td align="left">D8Mit98</td><td align="left">28.00</td><td align="left"><italic>Dlc1</italic> (deleted in liver cancer 1)</td><td char="." align="char">21.00</td><td align="left">[<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr>
###xml 2466 2467 2466 2467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">o</italic>
###xml 2461 2468 2461 2468 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">O20 (<italic>o</italic>)</td>
###xml 2468 2475 2468 2475 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">D8Mit66</td>
###xml 2475 2480 2475 2480 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">28.00</td>
###xml 2480 2483 2480 2483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ltq</italic>
###xml 2480 2500 2480 2500 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Ltq</italic> (lung tumor QTL)</td>
###xml 2500 2505 2500 2505 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">30.00</td>
###xml 2506 2508 2506 2508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR63">63</xref>
###xml 2505 2509 2505 2509 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">[<xref ref-type="bibr" rid="CR63">63</xref>]</td>
###xml 2461 2509 2461 2509 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">O20 (<italic>o</italic>)</td><td align="left">D8Mit66</td><td align="left">28.00</td><td align="left"><italic>Ltq</italic> (lung tumor QTL)</td><td char="." align="char">30.00</td><td align="left">[<xref ref-type="bibr" rid="CR63">63</xref>]</td></tr>
###xml 647 2509 647 2509 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit29</td><td align="left">36.50</td><td align="left"><italic>Lynf4</italic> (Lymphocyte infiltration 4)</td><td char="." align="char">35.15</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit31</td><td align="left">38.50</td><td align="left"><italic>Skts11</italic> (skin tumor susceptibility 11)</td><td char="." align="char">36.50</td><td align="left">[<xref ref-type="bibr" rid="CR42">42</xref>]</td></tr><tr><td align="left"><bold><italic>Cypr4</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left">D6Mit31</td><td align="left">38.50</td><td align="left"><italic>Pas1c</italic> (pulmonary adenoma susceptibility 1c)</td><td char="." align="char">37.00</td><td align="left">[<xref ref-type="bibr" rid="CR43">43</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit327</td><td align="left">46.50</td><td align="left"><italic>Mmom3</italic> (mammary modifier of <italic>Min3</italic>)</td><td char="." align="char">38.50</td><td align="left">[<xref ref-type="bibr" rid="CR44">44</xref>]</td></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit10</td><td align="left">48.70</td><td align="left"><italic>Ots1</italic> (ovarian teratoma susceptibility 1)</td><td char="." align="char">40.00</td><td align="left">[<xref ref-type="bibr" rid="CR45">45</xref>]</td></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit334</td><td align="left">60.75</td><td align="left"><italic>Ltsd8</italic> (lung tumor shape-determining 8)</td><td char="." align="char">61.20</td><td align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit256</td><td align="left">60.95</td><td align="left"><italic>Lynf3</italic> (Lymphocyte infiltration 3)</td><td char="." align="char">61.20</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td align="left"><bold><italic>Cypr5</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left">D6Mit52</td><td align="left">61.40</td><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit370</td><td align="left">62.67</td><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit13</td><td align="left">63.60</td><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D4Mit37</td><td align="left">56.50</td><td align="left"><italic>Lci</italic> (liver cell immortalization)</td><td char="." align="char">57.50</td><td align="left">[<xref ref-type="bibr" rid="CR47">47</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D4Mit11</td><td align="left">57.40</td><td align="left"><italic>Naad4</italic> (Neu associated allelic deletion 4)</td><td char="." align="char">57.40</td><td align="left">[<xref ref-type="bibr" rid="CR48">48</xref>]</td></tr><tr><td align="left" rowspan="12"><bold><italic>Cypr6</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left" rowspan="12">D4Mit54</td><td align="left" rowspan="12">66.00</td><td align="left"><italic>Ril3</italic> (radiation-induced leukemia sensitivity 3)</td><td char="." align="char">60.00</td><td align="left">[<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td align="left"><italic>Sluc21</italic> (susceptibility to lung cancer 21)</td><td char="." align="char">63.00</td><td align="left">[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td align="left"><italic>Tlsr3</italic> (thymic lymphoma suppressor region 3)</td><td char="." align="char">63.10</td><td align="left">[<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td align="left"><italic>Stmn1</italic> (stathmin 1)</td><td char="." align="char">65.70</td><td align="left">[<xref ref-type="bibr" rid="CR51">51</xref>]</td></tr><tr><td align="left"><italic>Naad5</italic> (Neu associated allelic deletion 5)</td><td char="." align="char">66.00</td><td align="left">[<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr><tr><td align="left"><italic>Ltsd4</italic> (lung tumor shape-determining 4)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr><tr><td align="left"><italic>Sluc6</italic> (susceptibility to lung cancer 6)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR53">53</xref>]</td></tr><tr><td align="left"><italic>Lynf1</italic> (Lymphocyte infiltration 1)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td align="left"><italic>Ssic1</italic> (susceptibility to small intestinal cancer 1)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR54">54</xref>]</td></tr><tr><td align="left"><italic>Nbl1</italic> (neuroblastoma, suppression of tumorigenicity 1)</td><td char="." align="char">70.00</td><td align="left">[<xref ref-type="bibr" rid="CR55">55</xref>]</td></tr><tr><td align="left"><italic>Pcts</italic> (plasmacytoma susceptibility)</td><td char="." align="char">70.00</td><td align="left">[<xref ref-type="bibr" rid="CR56">56</xref>]</td></tr><tr><td align="left"><italic>Gct1</italic> (granulosa cell tumorigenesis 1)</td><td char="." align="char">71.00</td><td align="left">[<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D4Mit342</td><td align="left">77.50</td><td align="left"><italic>Pctr2</italic> (plasmacytoma resistance 2)</td><td char="." align="char">73.50</td><td align="left">[<xref ref-type="bibr" rid="CR58">58</xref>]</td></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D4Mit59</td><td align="left">78.90</td><td align="left"><italic>Tlsr2</italic> (thymic lymphoma suppressor region 2)</td><td char="." align="char">76.60</td><td align="left">[<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td align="left" rowspan="3">O20 (<italic>o</italic>)</td><td align="left" rowspan="3">Markers start at 1&#160;cM</td><td align="left" rowspan="3"/><td align="left"><italic>Scc8</italic> (colon tumor susceptibility 8)</td><td char="." align="char">4.0</td><td align="left">[<xref ref-type="bibr" rid="CR59">59</xref>]</td></tr><tr><td align="left"><italic>Poats1</italic> (post-ovarectomy adrenal tumor susceptibility 1)</td><td char="." align="char">8.0</td><td align="left">[<xref ref-type="bibr" rid="CR60">60</xref>]</td></tr><tr><td align="left"><italic>Ltsd3</italic> (lung tumor shape-determining 3)</td><td char="." align="char">10.00</td><td align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D8Mit155</td><td align="left">1.00</td><td align="left"><italic>Sluc20</italic> (susceptibility to lung cancer 20)</td><td char="." align="char">10.00</td><td align="left">[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td align="left" rowspan="2"><bold><italic>Cypr7</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left" rowspan="2">D8Mit3</td><td align="left" rowspan="2">10.00</td><td align="left"><italic>Lynf2</italic> (lymphocyte infiltration 2)</td><td char="." align="char">10.00</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td align="left"><italic>Mfhas1</italic> (malignant fibrous histiocytoma amplified sequence 1)</td><td char="." align="char">20.00</td><td align="left">[<xref ref-type="bibr" rid="CR61">61</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D8Mit98</td><td align="left">28.00</td><td align="left"><italic>Dlc1</italic> (deleted in liver cancer 1)</td><td char="." align="char">21.00</td><td align="left">[<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D8Mit66</td><td align="left">28.00</td><td align="left"><italic>Ltq</italic> (lung tumor QTL)</td><td char="." align="char">30.00</td><td align="left">[<xref ref-type="bibr" rid="CR63">63</xref>]</td></tr></tbody>
###xml 593 2509 593 2509 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Locus with border markers</th><th align="left">Marker</th><th align="left">cM</th><th align="left">Locus/Gene</th><th align="left">cM</th><th align="left">Reference</th></tr></thead><tbody><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit29</td><td align="left">36.50</td><td align="left"><italic>Lynf4</italic> (Lymphocyte infiltration 4)</td><td char="." align="char">35.15</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit31</td><td align="left">38.50</td><td align="left"><italic>Skts11</italic> (skin tumor susceptibility 11)</td><td char="." align="char">36.50</td><td align="left">[<xref ref-type="bibr" rid="CR42">42</xref>]</td></tr><tr><td align="left"><bold><italic>Cypr4</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left">D6Mit31</td><td align="left">38.50</td><td align="left"><italic>Pas1c</italic> (pulmonary adenoma susceptibility 1c)</td><td char="." align="char">37.00</td><td align="left">[<xref ref-type="bibr" rid="CR43">43</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit327</td><td align="left">46.50</td><td align="left"><italic>Mmom3</italic> (mammary modifier of <italic>Min3</italic>)</td><td char="." align="char">38.50</td><td align="left">[<xref ref-type="bibr" rid="CR44">44</xref>]</td></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit10</td><td align="left">48.70</td><td align="left"><italic>Ots1</italic> (ovarian teratoma susceptibility 1)</td><td char="." align="char">40.00</td><td align="left">[<xref ref-type="bibr" rid="CR45">45</xref>]</td></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit334</td><td align="left">60.75</td><td align="left"><italic>Ltsd8</italic> (lung tumor shape-determining 8)</td><td char="." align="char">61.20</td><td align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit256</td><td align="left">60.95</td><td align="left"><italic>Lynf3</italic> (Lymphocyte infiltration 3)</td><td char="." align="char">61.20</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td align="left"><bold><italic>Cypr5</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left">D6Mit52</td><td align="left">61.40</td><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit370</td><td align="left">62.67</td><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit13</td><td align="left">63.60</td><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D4Mit37</td><td align="left">56.50</td><td align="left"><italic>Lci</italic> (liver cell immortalization)</td><td char="." align="char">57.50</td><td align="left">[<xref ref-type="bibr" rid="CR47">47</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D4Mit11</td><td align="left">57.40</td><td align="left"><italic>Naad4</italic> (Neu associated allelic deletion 4)</td><td char="." align="char">57.40</td><td align="left">[<xref ref-type="bibr" rid="CR48">48</xref>]</td></tr><tr><td align="left" rowspan="12"><bold><italic>Cypr6</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left" rowspan="12">D4Mit54</td><td align="left" rowspan="12">66.00</td><td align="left"><italic>Ril3</italic> (radiation-induced leukemia sensitivity 3)</td><td char="." align="char">60.00</td><td align="left">[<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td align="left"><italic>Sluc21</italic> (susceptibility to lung cancer 21)</td><td char="." align="char">63.00</td><td align="left">[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td align="left"><italic>Tlsr3</italic> (thymic lymphoma suppressor region 3)</td><td char="." align="char">63.10</td><td align="left">[<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td align="left"><italic>Stmn1</italic> (stathmin 1)</td><td char="." align="char">65.70</td><td align="left">[<xref ref-type="bibr" rid="CR51">51</xref>]</td></tr><tr><td align="left"><italic>Naad5</italic> (Neu associated allelic deletion 5)</td><td char="." align="char">66.00</td><td align="left">[<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr><tr><td align="left"><italic>Ltsd4</italic> (lung tumor shape-determining 4)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr><tr><td align="left"><italic>Sluc6</italic> (susceptibility to lung cancer 6)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR53">53</xref>]</td></tr><tr><td align="left"><italic>Lynf1</italic> (Lymphocyte infiltration 1)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td align="left"><italic>Ssic1</italic> (susceptibility to small intestinal cancer 1)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR54">54</xref>]</td></tr><tr><td align="left"><italic>Nbl1</italic> (neuroblastoma, suppression of tumorigenicity 1)</td><td char="." align="char">70.00</td><td align="left">[<xref ref-type="bibr" rid="CR55">55</xref>]</td></tr><tr><td align="left"><italic>Pcts</italic> (plasmacytoma susceptibility)</td><td char="." align="char">70.00</td><td align="left">[<xref ref-type="bibr" rid="CR56">56</xref>]</td></tr><tr><td align="left"><italic>Gct1</italic> (granulosa cell tumorigenesis 1)</td><td char="." align="char">71.00</td><td align="left">[<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D4Mit342</td><td align="left">77.50</td><td align="left"><italic>Pctr2</italic> (plasmacytoma resistance 2)</td><td char="." align="char">73.50</td><td align="left">[<xref ref-type="bibr" rid="CR58">58</xref>]</td></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D4Mit59</td><td align="left">78.90</td><td align="left"><italic>Tlsr2</italic> (thymic lymphoma suppressor region 2)</td><td char="." align="char">76.60</td><td align="left">[<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td align="left" rowspan="3">O20 (<italic>o</italic>)</td><td align="left" rowspan="3">Markers start at 1&#160;cM</td><td align="left" rowspan="3"/><td align="left"><italic>Scc8</italic> (colon tumor susceptibility 8)</td><td char="." align="char">4.0</td><td align="left">[<xref ref-type="bibr" rid="CR59">59</xref>]</td></tr><tr><td align="left"><italic>Poats1</italic> (post-ovarectomy adrenal tumor susceptibility 1)</td><td char="." align="char">8.0</td><td align="left">[<xref ref-type="bibr" rid="CR60">60</xref>]</td></tr><tr><td align="left"><italic>Ltsd3</italic> (lung tumor shape-determining 3)</td><td char="." align="char">10.00</td><td align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D8Mit155</td><td align="left">1.00</td><td align="left"><italic>Sluc20</italic> (susceptibility to lung cancer 20)</td><td char="." align="char">10.00</td><td align="left">[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td align="left" rowspan="2"><bold><italic>Cypr7</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left" rowspan="2">D8Mit3</td><td align="left" rowspan="2">10.00</td><td align="left"><italic>Lynf2</italic> (lymphocyte infiltration 2)</td><td char="." align="char">10.00</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td align="left"><italic>Mfhas1</italic> (malignant fibrous histiocytoma amplified sequence 1)</td><td char="." align="char">20.00</td><td align="left">[<xref ref-type="bibr" rid="CR61">61</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D8Mit98</td><td align="left">28.00</td><td align="left"><italic>Dlc1</italic> (deleted in liver cancer 1)</td><td char="." align="char">21.00</td><td align="left">[<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D8Mit66</td><td align="left">28.00</td><td align="left"><italic>Ltq</italic> (lung tumor QTL)</td><td char="." align="char">30.00</td><td align="left">[<xref ref-type="bibr" rid="CR63">63</xref>]</td></tr></tbody></table>
###xml 511 2509 511 2509 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="45">Co-localization of the four <italic>Cypr</italic> loci with cancer susceptibility loci/genes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Locus with border markers</th><th align="left">Marker</th><th align="left">cM</th><th align="left">Locus/Gene</th><th align="left">cM</th><th align="left">Reference</th></tr></thead><tbody><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit29</td><td align="left">36.50</td><td align="left"><italic>Lynf4</italic> (Lymphocyte infiltration 4)</td><td char="." align="char">35.15</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit31</td><td align="left">38.50</td><td align="left"><italic>Skts11</italic> (skin tumor susceptibility 11)</td><td char="." align="char">36.50</td><td align="left">[<xref ref-type="bibr" rid="CR42">42</xref>]</td></tr><tr><td align="left"><bold><italic>Cypr4</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left">D6Mit31</td><td align="left">38.50</td><td align="left"><italic>Pas1c</italic> (pulmonary adenoma susceptibility 1c)</td><td char="." align="char">37.00</td><td align="left">[<xref ref-type="bibr" rid="CR43">43</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit327</td><td align="left">46.50</td><td align="left"><italic>Mmom3</italic> (mammary modifier of <italic>Min3</italic>)</td><td char="." align="char">38.50</td><td align="left">[<xref ref-type="bibr" rid="CR44">44</xref>]</td></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit10</td><td align="left">48.70</td><td align="left"><italic>Ots1</italic> (ovarian teratoma susceptibility 1)</td><td char="." align="char">40.00</td><td align="left">[<xref ref-type="bibr" rid="CR45">45</xref>]</td></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit334</td><td align="left">60.75</td><td align="left"><italic>Ltsd8</italic> (lung tumor shape-determining 8)</td><td char="." align="char">61.20</td><td align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit256</td><td align="left">60.95</td><td align="left"><italic>Lynf3</italic> (Lymphocyte infiltration 3)</td><td char="." align="char">61.20</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td align="left"><bold><italic>Cypr5</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left">D6Mit52</td><td align="left">61.40</td><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit370</td><td align="left">62.67</td><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit13</td><td align="left">63.60</td><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D4Mit37</td><td align="left">56.50</td><td align="left"><italic>Lci</italic> (liver cell immortalization)</td><td char="." align="char">57.50</td><td align="left">[<xref ref-type="bibr" rid="CR47">47</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D4Mit11</td><td align="left">57.40</td><td align="left"><italic>Naad4</italic> (Neu associated allelic deletion 4)</td><td char="." align="char">57.40</td><td align="left">[<xref ref-type="bibr" rid="CR48">48</xref>]</td></tr><tr><td align="left" rowspan="12"><bold><italic>Cypr6</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left" rowspan="12">D4Mit54</td><td align="left" rowspan="12">66.00</td><td align="left"><italic>Ril3</italic> (radiation-induced leukemia sensitivity 3)</td><td char="." align="char">60.00</td><td align="left">[<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td align="left"><italic>Sluc21</italic> (susceptibility to lung cancer 21)</td><td char="." align="char">63.00</td><td align="left">[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td align="left"><italic>Tlsr3</italic> (thymic lymphoma suppressor region 3)</td><td char="." align="char">63.10</td><td align="left">[<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td align="left"><italic>Stmn1</italic> (stathmin 1)</td><td char="." align="char">65.70</td><td align="left">[<xref ref-type="bibr" rid="CR51">51</xref>]</td></tr><tr><td align="left"><italic>Naad5</italic> (Neu associated allelic deletion 5)</td><td char="." align="char">66.00</td><td align="left">[<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr><tr><td align="left"><italic>Ltsd4</italic> (lung tumor shape-determining 4)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr><tr><td align="left"><italic>Sluc6</italic> (susceptibility to lung cancer 6)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR53">53</xref>]</td></tr><tr><td align="left"><italic>Lynf1</italic> (Lymphocyte infiltration 1)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td align="left"><italic>Ssic1</italic> (susceptibility to small intestinal cancer 1)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR54">54</xref>]</td></tr><tr><td align="left"><italic>Nbl1</italic> (neuroblastoma, suppression of tumorigenicity 1)</td><td char="." align="char">70.00</td><td align="left">[<xref ref-type="bibr" rid="CR55">55</xref>]</td></tr><tr><td align="left"><italic>Pcts</italic> (plasmacytoma susceptibility)</td><td char="." align="char">70.00</td><td align="left">[<xref ref-type="bibr" rid="CR56">56</xref>]</td></tr><tr><td align="left"><italic>Gct1</italic> (granulosa cell tumorigenesis 1)</td><td char="." align="char">71.00</td><td align="left">[<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D4Mit342</td><td align="left">77.50</td><td align="left"><italic>Pctr2</italic> (plasmacytoma resistance 2)</td><td char="." align="char">73.50</td><td align="left">[<xref ref-type="bibr" rid="CR58">58</xref>]</td></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D4Mit59</td><td align="left">78.90</td><td align="left"><italic>Tlsr2</italic> (thymic lymphoma suppressor region 2)</td><td char="." align="char">76.60</td><td align="left">[<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td align="left" rowspan="3">O20 (<italic>o</italic>)</td><td align="left" rowspan="3">Markers start at 1&#160;cM</td><td align="left" rowspan="3"/><td align="left"><italic>Scc8</italic> (colon tumor susceptibility 8)</td><td char="." align="char">4.0</td><td align="left">[<xref ref-type="bibr" rid="CR59">59</xref>]</td></tr><tr><td align="left"><italic>Poats1</italic> (post-ovarectomy adrenal tumor susceptibility 1)</td><td char="." align="char">8.0</td><td align="left">[<xref ref-type="bibr" rid="CR60">60</xref>]</td></tr><tr><td align="left"><italic>Ltsd3</italic> (lung tumor shape-determining 3)</td><td char="." align="char">10.00</td><td align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D8Mit155</td><td align="left">1.00</td><td align="left"><italic>Sluc20</italic> (susceptibility to lung cancer 20)</td><td char="." align="char">10.00</td><td align="left">[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td align="left" rowspan="2"><bold><italic>Cypr7</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left" rowspan="2">D8Mit3</td><td align="left" rowspan="2">10.00</td><td align="left"><italic>Lynf2</italic> (lymphocyte infiltration 2)</td><td char="." align="char">10.00</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td align="left"><italic>Mfhas1</italic> (malignant fibrous histiocytoma amplified sequence 1)</td><td char="." align="char">20.00</td><td align="left">[<xref ref-type="bibr" rid="CR61">61</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D8Mit98</td><td align="left">28.00</td><td align="left"><italic>Dlc1</italic> (deleted in liver cancer 1)</td><td char="." align="char">21.00</td><td align="left">[<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D8Mit66</td><td align="left">28.00</td><td align="left"><italic>Ltq</italic> (lung tumor QTL)</td><td char="." align="char">30.00</td><td align="left">[<xref ref-type="bibr" rid="CR63">63</xref>]</td></tr></tbody></table></table-wrap>
In addition, the four Cypr loci described here co-localize with or are linked to a number of loci that control susceptibility to or patterns of progression of a variety of tumors that were independently described by different groups (Table 3). Cypr4 is linked to four such loci, Mmom1, Ots1, Pas1c, Skts11, Cypr5 to one locus, Ltsd8, Cypr6 to 15 loci (10 of them within 5 cM) Gct1, Ltsd4, Naad5, Nbl1, Pcts, Sluc6, Sluc21, Ssic1, Stmn1, Tlsr3, and Cypr7 to 7 loci Dlc1, Ltq, Ltsd3, Mfhas1, Sluc20, Scc8, Poats1.Table 3Co-localization of the four Cypr loci with cancer susceptibility loci/genesLocus with border markersMarkercMLocus/GenecMReferenceO20 (o)D6Mit2936.50Lynf4 (Lymphocyte infiltration 4)35.15[9]B10 (b)D6Mit3138.50Skts11 (skin tumor susceptibility 11)36.50[42]Cypr4(b)D6Mit3138.50Pas1c (pulmonary adenoma susceptibility 1c)37.00[43]B10 (b)D6Mit32746.50Mmom3 (mammary modifier of Min3)38.50[44]O20 (o)D6Mit1048.70Ots1 (ovarian teratoma susceptibility 1)40.00[45]O20 (o)D6Mit33460.75Ltsd8 (lung tumor shape-determining 8)61.20[46]B10 (b)D6Mit25660.95Lynf3 (Lymphocyte infiltration 3)61.20[9]Cypr5(b)D6Mit5261.40B10 (b)D6Mit37062.67O20 (o)D6Mit1363.60O20 (o)D4Mit3756.50Lci (liver cell immortalization)57.50[47]B10 (b)D4Mit1157.40Naad4 (Neu associated allelic deletion 4)57.40[48]Cypr6(b)D4Mit5466.00Ril3 (radiation-induced leukemia sensitivity 3)60.00[49]Sluc21 (susceptibility to lung cancer 21)63.00[30]Tlsr3 (thymic lymphoma suppressor region 3)63.10[50]Stmn1 (stathmin 1)65.70[51]Naad5 (Neu associated allelic deletion 5)66.00[52]Ltsd4 (lung tumor shape-determining 4)67.00[46]Sluc6 (susceptibility to lung cancer 6)67.00[53]Lynf1 (Lymphocyte infiltration 1)67.00[9]Ssic1 (susceptibility to small intestinal cancer 1)67.00[54]Nbl1 (neuroblastoma, suppression of tumorigenicity 1)70.00[55]Pcts (plasmacytoma susceptibility)70.00[56]Gct1 (granulosa cell tumorigenesis 1)71.00[57]B10 (b)D4Mit34277.50Pctr2 (plasmacytoma resistance 2)73.50[58]O20 (o)D4Mit5978.90Tlsr2 (thymic lymphoma suppressor region 2)76.60[50]O20 (o)Markers start at 1 cMScc8 (colon tumor susceptibility 8)4.0[59]Poats1 (post-ovarectomy adrenal tumor susceptibility 1)8.0[60]Ltsd3 (lung tumor shape-determining 3)10.00[46]B10 (b)D8Mit1551.00Sluc20 (susceptibility to lung cancer 20)10.00[30]Cypr7(b)D8Mit310.00Lynf2 (lymphocyte infiltration 2)10.00[9]Mfhas1 (malignant fibrous histiocytoma amplified sequence 1)20.00[61]B10 (b)D8Mit9828.00Dlc1 (deleted in liver cancer 1)21.00[62]O20 (o)D8Mit6628.00Ltq (lung tumor QTL)30.00[63]
###end p 44
###begin p 45
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr</italic>
Co-localization of the four Cypr loci with cancer susceptibility loci/genes
###end p 45
###begin p 46
###xml 179 181 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 371 373 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 430 432 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 617 619 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
IFNgamma has an important role in host defenses, in both innate and acquired immunity. IFNgamma is produced by many different cell types, such as by T cells, NK cells, NKT cells [35] upon their stimulation by antigens or mitogens. Macrophages and other accessory cells, such as dendritic cells, besides having a boosting effect on IFNgamma production by resting T cells [36] can themselves also produce large amounts of IFNgamma [37]. The interaction of T cells with antigen-presenting cells results in the production of IL-1, which then activates the T cells to produce IL-2, which promotes the IFNgamma production [38]. All IFNgamma inducers activate T cells either in a polyclonal (mitogen or antibodies) or a clonally restricted (antigen-specific) manner.
###end p 46
###begin p 47
###xml 177 179 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 462 464 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
IFNgamma (class II interferon) mediates broad immune responses to pathogens. It binds to IFNGR1/IFNGR2 receptor complex and uses JAK1/JAK2/STAT1 signaling pathway (reviewed in [39]). IFNgamma modulates the expression of major histocompatibility antigens on many different accessory cells, and thus stimulates interaction of these cells with T cells. Enhanced expression of class II antigens after IFNgamma treatment also takes place on cells of T and B lineage [40]. In the nonlymphoid organs, increased MHC antigens are found mainly on capillary endothelial cells, on renal tubular cells and on bronchiolar epithelial cells.
###end p 47
###begin p 48
###xml 274 276 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 277 279 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 281 283 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">41</xref>
###xml 373 375 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 436 440 428 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr</italic>
###xml 929 938 909 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr-Lynf</italic>
###xml 1137 1146 1113 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr-Lynf</italic>
###xml 169 173 <span type="species:ncbi:10090">mice</span>
###xml 358 363 <span type="species:ncbi:10090">mouse</span>
The role IFNgamma in suppression of tumor growth has been known for long time and the extensive literature cannot be reviewed here. Availability of genetically modified mice allowed to demonstrate also the role of IFNgamma in various aspects of anti-tumor immune responses [22-24, 41]. In some tests, it has been shown that this role may differ in different mouse strains [22]. The present data show not only a linkage between the four Cypr loci that control production of IFNgamma, but also an apparently negative correlation between the IFNgamma levels and intensity of infiltration, not only in the tested strains, but also when comparing different alleles. However, the statistical significance of this relationship is not clear. Moreover, we are comparing results of a short-term assay (production of IFNgamma in MLR) and a condition of long duration (intensity of lymphocyte infiltration in tumors). Before the responsible Cypr-Lynf genes are identified, it is difficult to assess, which of the multiple effects of IFNgamma on lymphocytes, other inflammatory cells, vasculature, and tumor cells modifies the level of infiltration. Cypr-Lynf congenic strains, currently under production, will create possibilities for more detailed studies of function of these genes.
###end p 48
###begin p 49
###xml 340 349 340 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr-Lynf</italic>
###xml 459 460 459 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 480 489 480 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr/Lynf</italic>
###xml 124 129 <span type="species:ncbi:9606">human</span>
###xml 229 234 <span type="species:ncbi:9606">human</span>
###xml 439 444 <span type="species:ncbi:10090">mouse</span>
The data presented here may be a suitable model for analysis of the potent modifying effects of infiltrating lymphocytes in human cancer. Although the mechanisms of the suppressive effects of lymphocyte infiltration on growth of human cancers are not known, it is interesting that there is an extensive genetic association between the four Cypr-Lynf loci and more than 20 loci controlling susceptibility to and progression of a variety of mouse tumors (Table 3). Each of the four Cypr/Lynf loci is linked to a number of susceptibility loci to various tumors including lung, skin, ovary, liver, mammary gland, lymphomas, leukemia, plasmacytoma, and histiocytoma. This multiplicity of tumor types affected by these loci/genes is compatible with a genetic effect that is not organ specific but possibly systemic, like control of effective immunosurveillance.
###end p 49
###begin p 50
###xml 214 219 <span type="species:ncbi:9606">human</span>
In conclusion, our data provide a novel link between genetic polymorphisms of regulation of lymphocyte activation and genetic variation in immunoregulation of tumor growth. Analysis of the genes involved and their human homologues may contribute to the understanding of individual predisposition to a high or low anti-tumor activity of lymphocytes and thus improve the decisions about personalized selection of appropriate therapies.
###end p 50
###begin p 51
We thank Neelima Kakarlapudi for useful comments. This work was supported by Grant Agency of the Czech Academy of Sciences (Grant GA AV A500520606), by Ministry of Education of the Czech Republic (Project Grant LC 06009), Grant Agency of the Czech Republic (Grant 310/08/H077), and Academy of Sciences of the Czech Republic (Project Grant AVOZ50520514). P.D. and L.Q. are supported by Roswell Park Cancer Institute's Institutional Funds and by NIH-NCI Grant 1R01CA127162-01.
###end p 51
###begin p 52
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 52
###begin title 53
References
###end title 53
###begin article-title 54
Paradoxical roles of the immune system during cancer development
###end article-title 54
###begin article-title 55
Why do we not all die of cancer at an early age?
###end article-title 55
###begin article-title 56
Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity
###end article-title 56
###begin article-title 57
The adaptive immune response to sporadic cancer
###end article-title 57
###begin article-title 58
###xml 51 56 <span type="species:ncbi:9606">human</span>
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
###end article-title 58
###begin article-title 59
Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins
###end article-title 59
###begin article-title 60
Tumor microvasculature as a barrier to antitumor immunity
###end article-title 60
###begin article-title 61
###xml 51 55 <span type="species:ncbi:10090">mice</span>
Lung tumor location and lymphocyte infiltration in mice are genetically determined
###end article-title 61
###begin article-title 62
###xml 91 95 91 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lynf</italic>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
Control of lymphocyte infiltration of lung tumors in mice by host's genes: mapping of four Lynf (lymphocyte infiltration) loci
###end article-title 62
###begin article-title 63
###xml 163 169 163 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">marif1</italic>
###xml 171 177 171 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">marif2</italic>
###xml 183 189 183 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">marif3</italic>
Genetic analysis of macrophage characteristics as a tool to identify tumor susceptibility genes: mapping of three macrophage-associated risk inflammatory factors, marif1, marif2, and marif3
###end article-title 63
###begin article-title 64
Novel loci controlling lymphocyte proliferative response to cytokines and their clustering with loci controlling autoimmune reactions, macrophage function and lung tumor susceptibility
###end article-title 64
###begin article-title 65
###xml 24 29 <span type="species:ncbi:9606">human</span>
Genetics HLA: the major human histocompatibility system
###end article-title 65
###begin article-title 66
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mls</italic>
Mls genes and self-superantigens
###end article-title 66
###begin article-title 67
Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses
###end article-title 67
###begin article-title 68
The mixed lymphocyte reaction in H-2K, H-2D, and non-H-2 incompatibility
###end article-title 68
###begin article-title 69
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Alan1</italic>
###xml 59 64 <span type="species:ncbi:10090">mouse</span>
A novel alloreactivity-controlling locus, Alan1, mapped to mouse chromosome 17
###end article-title 69
###begin article-title 70
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Alan2</italic>
###xml 74 79 <span type="species:ncbi:10090">mouse</span>
A new type of genetic regulation of allogeneic response. A novel locus on mouse chromosome 4, Alan2 controls MLC reactivity to three different alloantigens: C57BL/10, BALB/c and CBA
###end article-title 70
###begin article-title 71
Recombinant congenic strains-a new tool for analyzing genetic traits determined by more than one gene
###end article-title 71
###begin article-title 72
Identical genetic control of MLC reactivity to different MHC incompatibilities, independent of production of and response to IL-2
###end article-title 72
###begin article-title 73
###xml 146 148 146 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2</italic>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse model for analysis of non-MHC genes that influence allogeneic response: recombinant congenic strains of OcB/Dem series that carry identical H2 locus
###end article-title 73
###begin article-title 74
Regulation of interferon-gamma during innate and adaptive immune responses
###end article-title 74
###begin article-title 75
Suppression of lymphoma and epithelial malignancies effected by interferon gamma
###end article-title 75
###begin article-title 76
Deficiencies of GM-CSF and interferon gamma link inflammation and cancer
###end article-title 76
###begin article-title 77
Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction
###end article-title 77
###begin article-title 78
The role of tumor stroma in the interaction between tumor and immune system
###end article-title 78
###begin article-title 79
Immunologically important loci
###end article-title 79
###begin article-title 80
Genetic composition of the recombinant congenic strains
###end article-title 80
###begin article-title 81
Separation of multiple genes controlling the T-cell proliferative response to IL-2 and anti-CD3 using recombinant congenic strains
###end article-title 81
###begin article-title 82
###xml 21 26 <span type="species:ncbi:10090">mouse</span>
A genetic map of the mouse suitable for typing intraspecific crosses
###end article-title 82
###begin article-title 83
###xml 105 110 <span type="species:ncbi:10090">mouse</span>
Complexity of lung cancer modifiers: mapping of thirty genes and twenty-five interactions in half of the mouse genome
###end article-title 83
###begin article-title 84
Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results
###end article-title 84
###begin article-title 85
###xml 108 113 108 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr1</italic>
###xml 126 131 126 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr2</italic>
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cypr3</italic>
The production of two Th2 cytokines, interleukin-4 and interleukin-10, is controlled independently by locus Cypr1 and by loci Cypr2 and Cypr3, respectively
###end article-title 85
###begin article-title 86
The recombinant congenic strains for analysis of multigenic traits: genetic composition
###end article-title 86
###begin article-title 87
###xml 29 34 <span type="species:ncbi:10090">mouse</span>
###xml 75 80 <span type="species:ncbi:9606">human</span>
Cancer susceptibility in the mouse: genetics, biology and implications for human cancer
###end article-title 87
###begin article-title 88
Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors
###end article-title 88
###begin article-title 89
Interferon-gamma induction by lipopolysaccharide: dependence on interleukin 2 and macrophages
###end article-title 89
###begin article-title 90
IFN-gamma and pro-inflammatory cytokine production by antigen-presenting cells is dictated by intracellular thiol redox status regulated by oxygen tension
###end article-title 90
###begin article-title 91
###xml 37 42 <span type="species:ncbi:9606">human</span>
Regulation of IFN-gamma induction in human peripheral blood cells by exogenous and endogenously produced interleukin 2
###end article-title 91
###begin article-title 92
Interferon-inducible antiviral effectors
###end article-title 92
###begin article-title 93
Characterization of T-cell-soluble factors modulating the expression of Ia and H-2 antigens on BALB/c B lymphoma cell lines
###end article-title 93
###begin article-title 94
###xml 92 96 <span type="species:ncbi:10090">mice</span>
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice
###end article-title 94
###begin article-title 95
###xml 129 133 <span type="species:ncbi:10090">mice</span>
Allele-specific Hras mutations and genetic alterations at tumor susceptibility loci in skin carcinomas from interspecific hybrid mice
###end article-title 95
###begin article-title 96
###xml 124 128 <span type="species:ncbi:10090">mice</span>
At least four loci and gender are associated with susceptibility to the chemical induction of lung adenomas in A/J x BALB/c mice
###end article-title 96
###begin article-title 97
Identification of novel modifier loci of Apc Min affecting mammary tumor development
###end article-title 97
###begin article-title 98
###xml 40 46 <span type="species:ncbi:10090">murine</span>
Genetic dissection of susceptibility to murine ovarian teratomas that originate from parthenogenetic oocytes
###end article-title 98
###begin article-title 99
###xml 109 113 109 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ltsd</italic>
###xml 47 52 <span type="species:ncbi:10090">mouse</span>
Genetic analysis of three-dimensional shape of mouse lung tumors reveals eight lung tumor shape-determining (Ltsd) loci that are associated with tumor heterogeneity and symmetry
###end article-title 99
###begin article-title 100
###xml 106 109 106 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lci</italic>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
Most liver epithelial cell lines from C3B6F1 mice exhibit parentally-biased loss of heterozygosity at the Lci (Liver cell immortalization) locus on chromosome 4
###end article-title 100
###begin article-title 101
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Erbb2</italic>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
Fine allelotyping of Erbb2-induced mammary tumors in mice reveals multiple discontinuous candidate regions of tumor-suppressor loci
###end article-title 101
###begin article-title 102
Genetics of susceptibility for radiation-induced leukemia. Mapping of genes involved to chromosomes 1, 2, and 4, and implications for a viral etiology in the disease
###end article-title 102
###begin article-title 103
###xml 61 66 <span type="species:ncbi:10090">mouse</span>
A new candidate site for a tumor suppressor gene involved in mouse thymic lymphomagenesis is located on the distal part of chromosome 4
###end article-title 103
###begin article-title 104
###xml 29 34 <span type="species:ncbi:9606">human</span>
Molecular cloning of a novel human leukemia-associated gene. Evidence of conservation in animal species
###end article-title 104
###begin article-title 105
###xml 74 99 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
###xml 104 119 <span type="species:ncbi:10090">transgenic mice</span>
Elevated frequency of loss of heterozygosity in mammary tumors arising in mouse mammary tumor virus/neu transgenic mice
###end article-title 105
###begin article-title 106
###xml 97 102 97 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sluc5</italic>
###xml 106 112 106 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sluc14</italic>
###xml 79 84 <span type="species:ncbi:10090">mouse</span>
High frequency of interactions between lung cancer susceptibility genes in the mouse: mapping of Sluc5 to Sluc14
###end article-title 106
###begin article-title 107
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ssic1</italic>
###xml 88 93 <span type="species:ncbi:10090">mouse</span>
A gene for susceptibility to small intestinal cancer, ssic1, maps to the distal part of mouse chromosome 4
###end article-title 107
###begin article-title 108
###xml 62 65 62 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAN</italic>
###xml 26 31 <span type="species:ncbi:10090">mouse</span>
###xml 36 39 <span type="species:ncbi:10116">rat</span>
###xml 56 61 <span type="species:ncbi:9606">human</span>
Chromosome mapping of the mouse and rat homologs of the human DAN gene, D1S1733E
###end article-title 108
###begin article-title 109
###xml 58 63 <span type="species:ncbi:10090">mouse</span>
Genetic mapping of tumor susceptibility genes involved in mouse plasmacytomagenesis
###end article-title 109
###begin article-title 110
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gct1</italic>
###xml 114 119 <span type="species:ncbi:10090">mouse</span>
Distal Chr 4 harbors a genetic locus (Gct1) fundamental for spontaneous ovarian granulosa cell tumorigenesis in a mouse model
###end article-title 110
###begin article-title 111
Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene
###end article-title 111
###begin article-title 112
###xml 43 55 43 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scc6 to Scc9</italic>
###xml 63 68 <span type="species:ncbi:10090">mouse</span>
Four new colon cancer susceptibility loci, Scc6 to Scc9 in the mouse
###end article-title 112
###begin article-title 113
###xml 49 53 <span type="species:ncbi:10090">mice</span>
Adrenal gland tumorigenesis after gonadectomy in mice is a complex genetic trait driven by epistatic loci
###end article-title 113
###begin article-title 114
###xml 89 94 <span type="species:ncbi:10090">mouse</span>
Large-scale cDNA analysis reveals phased gene expression patterns during preimplantation mouse development
###end article-title 114
###begin article-title 115
DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development.
###end article-title 115
###begin article-title 116
###xml 93 97 <span type="species:ncbi:10090">mice</span>
Linkage disequilibrium mapping of novel lung tumor susceptibility quantitative trait loci in mice
###end article-title 116
###begin title 117
Abbreviations
###end title 117
###begin p 118
Cytokine production
###end p 118
###begin p 119
Lymphocyte infiltration
###end p 119
###begin p 120
Mixed lymphocyte culture
###end p 120
###begin p 121
Mixed lymphocyte reaction
###end p 121
###begin p 122
Quantitative trait locus
###end p 122

